

1 Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the 2 United States

3 Amanda C Perofsky^{1,2*}, John Huddleston³, Chelsea Hansen^{1,2}, John R Barnes⁴, Thomas Rowe⁴, Xiyan
4 Xu⁴, Rebecca Kondor⁴, David E Wentworth⁴, Nicola Lewis⁵, Lynne Whittaker⁵, Burcu Ermetal⁵, Ruth
5 Harvey⁵, Monica Galiano⁵, Rodney Stuart Daniels⁵, John W McCauley⁵, Seiichiro Fujisaki⁶, Kazuya
6 Nakamura⁶, Noriko Kishida⁶, Shinji Watanabe⁶, Hideki Hasegawa⁶, Sheena G Sullivan⁷, Ian G Barr⁷,
7 Kanta Subbarao⁷, Florian Krammer^{8,9}, Trevor Bedford^{2,3,10,11}, Cécile Viboud¹

8 9 Affiliations

- 10 1. Fogarty International Center, National Institutes of Health, United States
- 11 2. Brotman Baty Institute for Precision Medicine, University of Washington, United States
- 12 3. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, United States
- 13 4. Virology Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization
14 and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention (CDC), United
15 States
- 16 5. WHO Collaborating Centre for Reference and Research on Influenza, Crick Worldwide Influenza
17 Centre, The Francis Crick Institute, United Kingdom
- 18 6. Influenza Virus Research Center, National Institute of Infectious Diseases, Japan
- 19 7. WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute
20 for Infection and Immunity, Department of Microbiology and Immunology, The University of
21 Melbourne, The Peter Doherty Institute for Infection and Immunity, Australia
- 22 8. Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine
23 at Mount Sinai, United States
- 24 9. Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at
25 Mount Sinai, United States
- 26 10. Department of Genome Sciences, University of Washington, United States
- 27 11. Howard Hughes Medical Institute, Seattle, United States

28
29 *Correspondence to amanda.perofsky@nih.gov

30 31 Abstract

32 Influenza viruses continually evolve new antigenic variants, through mutations in epitopes of their major
33 surface proteins, hemagglutinin (HA) and neuraminidase (NA). Antigenic drift potentiates the reinfection
34 of previously infected individuals, but the contribution of this process to variability in annual epidemics is
35 not well understood. Here we link influenza A(H3N2) virus evolution to regional epidemic dynamics in the
36 United States during 1997–2019. We integrate phenotypic measures of HA antigenic drift and sequence-
37 based measures of HA and NA fitness to infer antigenic and genetic distances between viruses
38 circulating in successive seasons. We estimate the magnitude, severity, timing, transmission rate, age-
39 specific patterns, and subtype dominance of each regional outbreak and find that genetic distance based
40 on broad sets of epitope sites is the strongest evolutionary predictor of A(H3N2) virus epidemiology.
41 Increased HA and NA epitope distance between seasons correlates with larger, more intense epidemics,
42 higher transmission, greater A(H3N2) subtype dominance, and a greater proportion of cases in adults
43 relative to children, consistent with increased population susceptibility. Based on random forest models,
44 A(H1N1) incidence impacts A(H3N2) epidemics to a greater extent than viral evolution, suggesting that
45 subtype interference is a major driver of influenza A virus infection dynamics, presumably via
46 heterosubtypic cross-immunity.

47 Introduction

48 Influenza viruses continually accumulate genetic changes in epitopes of two major surface proteins,
49 hemagglutinin (HA) and neuraminidase (NA), in a process known as “antigenic drift.” Though individual
50 hosts develop long-lasting immunity to specific influenza virus strains after infection, antigenic drift helps
51 the virus to escape immune recognition, leaving previously exposed hosts susceptible to reinfection and
52 necessitating the regular updates to the antigens included in the influenza vaccine [1]. While antigenic
53 drift aids immune escape, prospective cohort studies and modeling of surveillance data also indicate that
54 reinfection by antigenically homologous viruses occurs on average every 1-4 years, due to the waning of
55 protection over time and antigenic drift [2,3].

56 Among the influenza virus types that routinely co-circulate in humans (A and B), type A viruses,
57 particularly subtype A(H3N2), experience the fastest rates of antigenic evolution and cause the most
58 substantial morbidity and mortality [4-7]. Seasonal influenza A viruses (IAV) cause annual winter
59 epidemics in temperate zones of the Northern and Southern Hemispheres and circulate year-round in
60 tropical regions [8]. Influenza A epidemic burden fluctuates substantially from year to year [9], and there is
61 much scientific interest in disentangling the relative roles of viral evolution, prior immunity, human
62 behavior, and climatic factors in driving this seasonal variability. Climatic factors, such as humidity and
63 temperature, have been implicated in the seasonality and timing of winter outbreaks in temperate regions
64 [10-14], while contact and mobility patterns contribute to the seeding of new outbreaks and geographic
65 spread [10,15-19]. A principal requirement for the recurrence of epidemics is a sufficient and continuous
66 source of susceptible individuals, which is determined by the degree of cross-immunity between the
67 surface antigens of currently circulating viruses and functional antibodies elicited by prior infection or
68 vaccination in a population.

69 Because mutations to the HA1 region of the HA protein are considered to drive the majority of antigenic
70 drift [20,21], influenza virus genetic and antigenic surveillance have focused primarily on HA, and official
71 influenza vaccine formulations prescribe the amount of HA [22]. Yet, evidence for the effect of HA drift on
72 influenza epidemic dynamics remains conflicting. Theoretical and empirical studies have shown that HA
73 drift between currently circulating viruses and the previous season’s viruses is expected to cause earlier,
74 larger, more severe, or more synchronized epidemics; however, the majority of these studies were limited
75 to the pre 2009 influenza pandemic period [6,17,23-28]. Information on HA evolution has been shown to
76 improve forecasts of seasonal influenza dynamics in Israel and the United States [29,30], but recent
77 research has also found that HA evolution is not predictive of epidemic size in Australia [31] or epidemic
78 timing in the United States [16]. A caveat is that many of these studies used binary indicators to study
79 seasonal antigenic change, defined as seasons in which circulating viruses were antigenically distinct
80 from the vaccine reference strain [16,17,24,31,32]. This may obscure epidemiologically relevant patterns,
81 as positive selection in HA and NA is both episodic and continuous [6,32-37]. Past research has also
82 typically focused on serological and sequence-based measures of viral evolution in isolation, and the
83 relative importance of these two approaches in predicting epidemic dynamics has not been systematically
84 assessed. Further, to the best of our knowledge, the epidemiologic impact of NA evolution has not been
85 explored.

86 There has been recent recognition of NA’s role in virus inhibiting antibodies and its potential as a vaccine
87 target [38-40]. Though antibodies against NA do not prevent influenza infection, NA immunity attenuates
88 the severity of infection by limiting viral replication [41-46], and NA-specific antibody titers are an
89 independent correlate of protection in both field studies and human challenge trials [47-49]. Lastly, the
90 phenomenon of interference between influenza A subtypes, modulated by immunity to conserved T-cell
91 epitopes [50-52], has long been debated [53,54]. Interference effects are most pronounced during
92 pandemic seasons, leading to troughs or even replacement of the resident subtype in some pandemics
93 [55], but the contribution of heterosubtypic interference to annual dynamics is unclear [2,56-59].

94 Here, we link A(H3N2) virus evolutionary dynamics to epidemiologic surveillance data in the United States
95 over the course of 22 influenza seasons prior to the coronavirus disease (COVID-19) pandemic,
96 considering the full diversity of viruses circulating in this period. We analyze a variety of antigenic and
97 genetic markers of HA and NA evolution against multiple indicators characterizing the epidemiology and
98 disease burden of annual outbreaks. We find a signature of both HA and NA antigenic drift in surveillance
99 data, with a more pronounced relationship in epitope change rather than the serology-based indicator,
100 along with a major effect of subtype interference. Our study has implications for surveillance of
101 evolutionary indicators that are most relevant for population impact and for prediction of influenza burden
102 on inter-annual timeframes.

103 **Results**

104 Our study focuses on the impact of A(H3N2) virus evolution on seasonal epidemics from seasons 1997-
105 1998 to 2018-2019 in the US; whenever possible, we make use of regionally disaggregated indicators
106 and analyses. We start by identifying multiple indicators of influenza evolution each season based on
107 changes in HA and NA. Next, we compile influenza virus subtype-specific incidence time series for US
108 Department of Health and Human Service (HHS) regions and estimate multiple indicators characterizing
109 influenza A(H3N2) epidemic dynamics each season, including epidemic burden, severity, intensity,
110 type/subtype dominance, timing, and the age distribution of cases. We then assess univariate
111 relationships between indicators of evolution and epidemic characteristics. Lastly, we measure the
112 relative importance of viral evolution, heterosubtypic interference, and prior immunity in predicting
113 regional A(H3N2) epidemic dynamics, using multivariable regression models and random forest models.

114 **Indicators of influenza A(H3N2) evolution**

115 We characterized seasonal patterns of genetic and antigenic evolution among A(H3N2) viruses
116 circulating from 1997 to 2019, using HA and NA sequence data shared via the Global Initiative on Sharing
117 Avian Influenza Data (GISAID) EpiFlu database [60] and ferret hemagglutination inhibition (HI) assay data
118 shared by the WHO Global Influenza Surveillance and Response System (GISRS) Collaborating Centers
119 in London, Melbourne, Atlanta, and Tokyo. Prior to constructing phylogenetic trees, we subsampled
120 sequences to representative sets of 50 viruses per month, with preferential sampling for North American
121 sequences. Although our study is US-focused, we used a global dataset because US-collected
122 sequences and HI titers were sometimes sparse during the earlier seasons of the study. Time-resolved
123 phylogenies of HA and NA genes are shown in Figure 1.

124 Our choice of evolutionary indicators builds on earlier studies that found hemagglutination inhibition (HI)
125 phenotype or HA sequence data beneficial in forecasting seasonal influenza virus evolution [35,61-63] or
126 annual epidemic dynamics [27,29,30] (Table 1). Historically, HI serological assays were considered the
127 gold standard for measuring immune cross-reactivity between viruses, yet measurements are available
128 for only a subset of viruses. To overcome this limitation, we used a computational approach that maps HI
129 titer measurements onto the HA phylogenetic tree to infer antigenic phenotypes [35,63]. Importantly, this
130 model infers the antigenicity of virus isolates that lack HI titer measurements, which comprise the majority
131 of HA sequences in GISAID. Our sequence-based measures of drift counted substitutions at epitope sites
132 in the globular head domains of HA and NA, identified through monoclonal antibody escape or protein
133 crystal structure: 129 sites in HA epitope regions A to E [21,64-67], 7 sites adjacent to the HA receptor
134 binding site (RBS) [68], and 223 or 53 sites in NA epitope regions A to C [34,69].

135 We included other indicators of viral fitness for HA and NA, including the number of substitutions at non-
136 epitope sites (mutational load) [35,61] and the average rate of phylogenetic branching in a season (local
137 branching index, LBI) [35,62]. We also calculated the Shannon entropy of LBI values, which considers the
138 richness and relative abundances of viral clades with different growth rates. Lastly, we counted the
139 number of substitutions at epitope sites in the HA stalk domain (stalk footprint distance) [70]. Although the
140 majority of the antibody-mediated response to HA is directed to the immunodominant HA head,

141 antibodies towards the highly conserved immunosubdominant stalk domain of HA are widely prevalent in
142 older individuals, although at low levels [71-73]. We considered stalk footprint distance to be our “control”
143 metric for drift, given the HA stalk evolves at a significantly slower rate than the HA head [70].

144 To measure antigenic distances between consecutive seasons, we calculated mean genetic distances at
145 epitope sites or mean \log_2 titer distances from HI titer measurements (Figure 1), between viruses
146 circulating in the current season t and the prior season $t-1$ year (one season lag) or two prior seasons ago
147 $t-2$ years (two season lag). These time windows generated seasonal antigenic distances consistent with
148 empirical and theoretical studies characterizing transitions between H3 or N2 antigenic clusters
149 [6,32,35,55,62,74], with H3 epitope distance and HI \log_2 titer distance, at two-season lags, and N2
150 epitope distance, at one-season lags, capturing expected “jumps” in antigenic drift during key seasons
151 that have been previously associated with major antigenic transitions [32], such as the seasons
152 dominated by A/Sydney/5/1997-like strains (SY97) (1997-1998, 1998-1999, 1999-2000) and the 2003-
153 2004 season dominated by A/Fujian/411/2002-like strains (FU02) (Figures S1-S2). Prior studies explicitly
154 linking antigenic drift to epidemic size or severity also support a one-year [6] or two-year time window of
155 drift [26,27]. Given that protective immunity wanes after 1-4 years, we would also expect these
156 timeframes to return the greatest signal in epidemiological surveillance data.

157 We measured pairwise correlations between seasonal indicators of HA and NA evolution to assess their
158 degree of concordance. As expected, we found moderate-to-strong associations between HA epitope
159 distance and HI \log_2 titer distance and HA RBS distance and HI \log_2 titer distance (Figure S1-S3).
160 Consistent with prior serological studies [39,75,76], epitope distances in HA and NA were not correlated
161 (one-season lag: Spearman’s $\rho = 0.25$, $P = 0.26$; two-season lag: $\rho = 0.15$, $P = 0.5$; Figures S2-S4).
162 Seasonal diversity of HA and NA LBI values was negatively correlated with NA epitope distance (Figure
163 S3), suggesting that selective sweeps follow the emergence of drifted variants.

164 **Associations between A(H3N2) evolution and epidemic dynamics**

165 We explored relationships between viral evolution and variation in A(H3N2) epidemic dynamics from
166 seasons 1997-1998 to 2018-2019, excluding the 2009 A(H1N1) pandemic, using syndromic and virologic
167 surveillance data collected by the US CDC and WHO.

168 We estimated weekly incidences of influenza A(H3N2), A(H1N1), and B in 10 HHS regions by multiplying
169 the influenza-like illness (ILI) rate – the proportion of outpatient encounters for ILI, weighted by regional
170 population size – by the regional proportion of respiratory samples testing positive for each influenza
171 type/subtype (percent positive) [57,77]. We combined pre-2009 seasonal A(H1N1) viruses and
172 A(H1N1)pdm09 viruses as A(H1N1) and the Victoria and Yamagata lineages of influenza B viruses as
173 influenza B. Weekly incidences of influenza A(H3N2), A(H1N1), and type B, averaged across the 10 HHS
174 regions, are shown in Figure 2. Weekly regional incidences, which show variability in the timing and
175 intensity of annual epidemics, are shown in Figure 2 and Figure S5. Based on these incidence time
176 series, we measured indicators of epidemic burden, intensity, severity, subtype dominance, timing, and
177 age-specific patterns during each non-pandemic season and assessed their univariate relationships with
178 each indicator of HA and NA evolution, which we describe in turn below. Seasonal characteristics of
179 A(H3N2) epidemic dynamics were based on epidemic size, defined as the cumulative weekly incidence;
180 peak incidence, defined as the maximum weekly incidence; excess mortality attributable to A(H3N2), an
181 indicator of epidemic severity; transmissibility, defined as the maximum time-varying effective
182 reproductive number, effective R_t ; and epidemic intensity, defined as the inverse Shannon entropy of the
183 weekly incidence distribution (i.e., the sharpness of the epidemic curve). See methods and Table 2 for
184 details on all epidemic metrics and Figure S6 for pairwise correlations between metrics.

185 Two sequence-based measures based on broad sets of epitope sites exhibited stronger relationships with
186 seasonal epidemic burden and transmissibility than the serology-based measure, HI \log_2 titer distance.
187 Both H3 epitope distance ($t - 2$) and N2 epitope distance ($t - 1$) correlated with increased epidemic size

188 (linear models, LMs: H3, adjusted $R^2 = 0.37$, $P = 0.03$; N2: $R^2 = 0.26$, $P = 0.08$) and peak incidence (LMs,
189 H3: $R^2 = 0.4$, $P = 0.02$; N2: $R^2 = 0.33$, $P = 0.04$) and higher effective R_t (generalized linear models, GLMs:
190 H3, $R^2 = 0.38$, $P = 0.05$; N2, $R^2 = 0.32$, $P = 0.03$) (regression results: Figure 3, Spearman's correlations:
191 Figure S7). HI \log_2 titer distance ($t - 2$) exhibited positive but non-significant associations with different
192 measures of epidemic impact (Figure 3, Figure S7). Seasonal diversity in the growth rates of circulating
193 lineages in the current t or prior season ($t - 1$) had strong negative correlations with effective R_t (GLMs,
194 H3 ($t - 1$): $R^2 = 0.49$, $P = 0.009$; N2, t : $R^2 = 0.46$, $P = 0.006$) and epidemic intensity (Beta GLMs, H3 ($t -$
195 1): $R^2 = 0.45$, $P = 0.003$; N2, t : $R^2 = 0.51$, $P = 0.001$) (Figures S7-S8). Seasonal mean LBI exhibited
196 similar but slightly weaker correlations with effective R_t and epidemic intensity. Pneumonia and influenza
197 excess mortality attributable to A(H3N2) also increased with H3 epitope distance, though this relationship
198 was not statistically significant (Figure S9). The remaining indicators of viral evolution, including H3 and
199 N2 non-epitope distance (mutational load), H3 RBS distance, and H3 stalk footprint distance had weak,
200 non-significant correlations with the different measures of epidemic impact (Figure S7).

201 We explored whether evolutionary changes in A(H3N2) may predispose this subtype to dominate
202 influenza virus circulation in a given season. A(H3N2) subtype dominance – the proportion of influenza
203 positive samples typed as A(H3N2) – increased with H3 epitope distance ($t - 2$) and N2 epitope distance
204 ($t - 1$) (Beta GLMs, H3: $R^2 = 0.32$, $P = 0.05$; N2: $R^2 = 0.34$, $P = 0.03$; Figure 4, Figure S7). Figure 4
205 illustrates this relationship at the regional level across two seasons in which A(H3N2) was nationally
206 dominant, but where antigenic change differed. In 2003-2004, we observed widespread dominance of
207 A(H3N2) viruses after the emergence of the novel antigenic cluster, FU02 (A/Fujian/411/2002-like
208 strains). In contrast, there was substantial regional heterogeneity in subtype circulation during 2007-2008,
209 a season in which A(H3N2) viruses were antigenically similar to those from the previous season. Patterns
210 in type/subtype circulation across all influenza seasons in our study period are shown in Figure S10. As
211 observed for the 2003-2004 season, widespread A(H3N2) dominance tends to coincide with major
212 antigenic transitions (e.g., A/Sydney/5/1997 (SY97) seasons, 1997-1998 to 1999-2000;
213 A/California/7/2004 (CA04) season, 2004-2005), though this was not universally the case (e.g.,
214 A/Perth/16/2009 (PE09) season, 2010-2011).

215 Next, we tested for associations between A(H3N2) evolution and epidemic timing, including onset week,
216 defined as the winter changepoint in incidence [16], and peak week, defined as the first week of
217 maximum incidence; spatiotemporal synchrony, measured as the variation (standard deviation, s.d.) in
218 regional onset and peak timing; and epidemic speed, including seasonal duration and the number of
219 weeks from onset to peak (Table 2, Figure S11). Seasonal duration increased with H3 or N2 LBI diversity
220 in the current t or prior season ($t - 1$) (Gamma GLMs, H3, t : $R^2 = 0.6$; $P = 0.001$; N2, t : $R^2 = 0.6$; $P =$
221 0.002 ; Figures S11-S12), while the number of days from epidemic onset to peak shortened with
222 increasing N2 epitope distance ($t - 1$) (Gamma GLM, $R^2 = 0.31$, $P = 0.04$; Figure S11, Figure S13). Onset
223 and peak timing tended to be earlier in seasons with increased H3 and N2 antigenic novelty, but
224 correlations were not statistically significant (Figure S14). A(H3N2) evolution did not correlate with the
225 degree of spatiotemporal synchrony across HHS regions.

226 Lastly, we considered the effects of antigenic change on the age distribution of outpatient ILI cases, with
227 the expectation that the proportion of cases in children would decrease in seasons with greater antigenic
228 novelty, due to drifted variants' increased ability to infect more immunologically experienced adults [7,78].
229 Consistent with this hypothesis, N2 epitope distance from prior seasons was negatively correlated with
230 the fraction of cases in children aged < 5 years (LMs, one-season lag: $R^2 = 0.29$, $P = 0.1$; two-season lag:
231 $R^2 = 0.59$, $P = 0.003$) and individuals aged 5-24 years (one-season lag: $R^2 = 0.38$, $P = 0.04$; two-season
232 lag: $R^2 = 0.17$, $P = 0.18$) and negatively correlated with the fraction of cases in adults aged 25-64 years
233 (one-season lag: $R^2 = 0.36$, $P = 0.05$; two-season lag: $R^2 = 0.49$, $P = 0.01$) and ≥ 65 years (one-season
234 lag: $R^2 = 0.39$, $P = 0.01$; two-season lag: $R^2 = 0.33$, $P = 0.05$) (Figures S15-S16). As observed in Gostic
235 et al. [78], H3 epitope distance ($t - 2$) had negative but non-significant associations with the fraction of
236 cases in children and positive but non-significant associations with the fraction of cases in adult age
237 groups (Figures S15-S16).

238 **Effects of heterosubtypic viral interference on A(H3N2) epidemic burden and timing**

239 We investigated the effects of influenza type/subtype interference – proxied by influenza A(H1N1) and B
240 epidemic size – on A(H3N2) incidence during annual outbreaks. Across the entire study period, we
241 observed moderate-to-strong, non-linear relationships between A(H1N1) epidemic size and A(H3N2)
242 epidemic size (GLM, $R^2 = 0.65$, $P = 0.01$), peak incidence ($R^2 = 0.66$, $P = 0.02$), and excess mortality (all
243 age groups and ≥ 65 years, $R^2 = 0.57$, $P = 0.01$) (Figure 5, Figure S17), wherein A(H3N2) epidemic
244 burden and excess mortality decreased as A(H1N1) incidence increased. A(H1N1) epidemic size was
245 also significantly correlated with A(H3N2) effective R_t , exhibiting a negative, approximately linear
246 relationship (GLM, $R^2 = 0.45$, $P = 0.01$) (Figure 5). A(H3N2) epidemic intensity was negatively associated
247 with A(H1N1) epidemic size, but this relationship was not statistically significant (Beta GLM, $R^2 = 0.21$, P
248 $= 0.15$). Influenza B epidemic size was not significantly correlated with any A(H3N2) epidemic metrics
249 (Figure 5, Figure S17).

250 The internal gene segments NS, M, NP, PA, and PB2 of A(H3N2) viruses and pre-2009 seasonal
251 A(H1N1) viruses share a common ancestor [79] whereas A(H1N1)pdm09 viruses have a combination of
252 gene segments derived from swine and avian reservoirs that were not reported prior to the 2009
253 pandemic [80,81]. Because pre-2009 seasonal A(H1N1) viruses and A(H3N2) are more closely related,
254 seasonal A(H1N1) viruses may limit the circulation of A(H3N2) viruses to a greater extent than
255 A(H1N1)pdm09 viruses. As a sensitivity analysis, we measured correlations between A(H1N1) incidence
256 and A(H3N2) epidemic metrics separately for pre- and post-2009 pandemic time periods. Relationships
257 between different A(H3N2) epidemic metrics and A(H1N1) epidemic size were broadly similar for both
258 periods, with slightly stronger correlations observed during the pre-2009 period (Figure S18).

259 We compared A(H3N2) epidemic timing across A(H3N2) and A(H1N1) dominant seasons, which we
260 defined as when $\geq 70\%$ of influenza A positive samples are typed as A(H3N2) or
261 A(H1N1)/A(H1N1)pdm09, respectively. We applied a strict threshold for subtype dominance because
262 seasons with $< 70\%$ samples of one IAV subtype tended to have greater geographic heterogeneity in
263 circulation, resulting in regions with dominant subtypes that were not nationally dominant. A(H3N2)
264 epidemic onsets and peaks occurred, on average, three weeks earlier in A(H3N2) dominant seasons
265 (Wilcoxon test, $P < 0.0001$). In A(H1N1) dominant seasons, regional A(H3N2) epidemics exhibited greater
266 heterogeneity in epidemic timing (onset s.d.: H3 dominant seasons, 12.4 weeks versus H1 dominant
267 seasons, 16.3 weeks; peak s.d., H3 dominant seasons, 13.3 weeks versus H1 dominant seasons, 22.6
268 weeks; Wilcoxon tests, $P < 0.0001$) and were significantly shorter in duration compared to A(H3N2)
269 dominant seasons (median duration: H3 dominant seasons, 29 weeks versus H1 dominant seasons, 21
270 weeks; Wilcoxon test, $P < 0.0001$).

271 We applied a wavelet approach [82] to weekly time series of type/subtype-specific incidences to measure
272 more fine-scale differences in the relative timing of type/subtype circulation (Figure S19). A(H3N2)
273 incidence preceded A(H1N1) incidence during most seasons prior to 2009 and during the two seasons in
274 which A(H1N1)pdm09 was dominant, potentially because A(H3N2) viruses are more globally prevalent
275 and migrate between regions more frequently than A(H1N1) viruses [7]. There was not a clear
276 relationship between the direction of seasonal phase lags and A(H1N1) epidemic size (LM, $R^2 = 0.23$, $P =$
277 0.1 ; Figure S19). A(H3N2) incidence led influenza B incidence in all influenza seasons (positive phase
278 lag), irrespective of influenza B epidemic size (LM, $R^2 = 0.05$, $P = 0.5$; Figure S19).

279 **The relative impacts of viral evolution, heterosubtypic interference, and prior immunity on** 280 **A(H3N2) epidemic dynamics**

281 We implemented conditional inference random forest models to assess the relative importance of viral
282 evolution, type/subtype co-circulation, prior population immunity, and vaccine-related parameters in
283 predicting regional A(H3N2) epidemic metrics (Figure 6). We limited viral evolutionary indicators to H3
284 epitope distance ($t - 2$), N2 epitope distance ($t - 1$), HI \log_2 titer distance ($t - 2$), and H3 and N2 LBI

285 diversity in the current and prior season, due to weaker or non-significant correlations between the other
286 evolutionary metrics and epidemic burden (Figure S7). To account for potential type or subtype
287 interference, we included A(H1N1) epidemic size (A(H1N1) or A(H1N1)pdm09) and B epidemic size in the
288 current and prior season and the dominant IAV subtype in the prior season. We included A(H3N2)
289 epidemic size in the prior season as a proxy of natural prior immunity to A(H3N2). To account for vaccine-
290 induced immunity, we considered four categories of predictors and included estimates for the current and
291 prior seasons: seasonal vaccination coverage among adults (18-49 years coverage \times \geq 65 years
292 coverage), adjusted A(H3N2) vaccine effectiveness (VE), a combined metric of vaccination coverage and
293 A(H3N2) VE (18-49 years coverage \times \geq 65 years coverage \times VE), and H3 and N2 epitope distance
294 between currently circulating strains and the US vaccine reference strain. We could not include a
295 predictor for vaccination coverage in children or consider clade-specific VE estimates, because data were
296 not available for most seasons in our study. We did not predict excess mortality attributable to A(H3N2),
297 due to data limitation (one national estimate per season) and omitted models predicting epidemic timing,
298 due to weak or non-significant correlations between timing-related measures and most indicators of viral
299 evolution (Figure S11). Lastly, we could not separate our analysis into pre- and post-2009 pandemic
300 periods due to small sample sizes.

301 Based on variable importance scores, A(H1N1) epidemic size in the current season was the most
302 informative predictor of A(H3N2) epidemic size and peak incidence, followed by H3 epitope distance, and
303 the dominant IAV subtype in the previous season or N2 epitope distance (Figure 6). For A(H3N2) subtype
304 dominance, the highest ranked predictors were H3 epitope distance, N2 epitope distance, and the
305 dominant IAV subtype in the previous season (Figure 6). We note that we did not include A(H1N1)
306 epidemic size as a predictor in this model, due to its confounding with the target variable. For models of
307 A(H3N2) effective R_t and epidemic intensity, we observed less discernable differences in variable
308 importance scores across the set of candidate predictors (Figure 6). For the model of effective R_t , N2 LBI
309 diversity in the current season, A(H1N1) epidemic size in the current season, and N2 epitope distance
310 between circulating strains and the vaccine strain were the highest ranked variables, while the most
311 important predictors of epidemic intensity were H3 and N2 LBI diversity in the current season and adult
312 vaccination coverage in the current and prior season. Variable importance rankings from LASSO (least
313 absolute shrinkage and selection operator) regression models were qualitatively similar to those from
314 random forest models, with A(H1N1) epidemic size in the current season, H3 and N2 epitope distance,
315 and the dominant IAV subtype in the prior season consistently retained across the best-tuned models of
316 epidemic size, peak incidence, and subtype dominance (Figure S20). Vaccine-related parameters and H3
317 antigenic drift (either H3 epitope distance or HI \log_2 titer distance) were retained in the best-tuned LASSO
318 models of effective R_t and epidemic intensity (Figure S20).

319 We measured correlations between observed values and model-predicted values at the HHS region level.
320 Among our various epidemic metrics, random forest models produced the most accurate predictions of
321 A(H3N2) subtype dominance ($\rho = 0.94$, regional range = 0.8 – 0.98), peak incidence (Spearman's $\rho =$
322 0.91, regional range = 0.73 – 0.95), and epidemic size ($\rho = 0.9$, regional range = 0.73 – 0.94), while
323 predictions of effective R_t and epidemic intensity were less accurate ($\rho = 0.8$, regional range = 0.65 –
324 0.91; $\rho = 0.78$, regional range = 0.63 – 0.91, respectively) (Figure 7). Random forest models tended to
325 underpredict most epidemic targets in seasons with substantial H3 antigenic transitions, in particular the
326 SY97 cluster seasons (1998-1999, 1999-2000) and the FU02 cluster season (2003-2004) (Figure 7).

327 For epidemic size and peak incidence, seasonal predictive error – root-mean-square error (RMSE) across
328 all regional predictions in a season – increased with H3 epitope distance (size, Spearman's $\rho = 0.51$, $P =$
329 0.02; peak, $\rho = 0.61$, $P = 0.007$) and N2 epitope distance (size, $\rho = 0.43$, $P = 0.06$; peak, $\rho = 0.46$, $P =$
330 0.04). For models of epidemic intensity, seasonal RMSE increased with N2 epitope distance ($\rho = 0.62$, $P =$
331 0.006) but not H3 epitope distance ($\rho = 0.07$, $P = 0.8$) (Figures S21-S22). The RMSE of effective R_t and
332 subtype dominance predictions were not significantly correlated with H3 or N2 epitope distance (Figures
333 S21-22).

334 To further refine our set of informative predictors, we performed multivariable regression with the top 10
335 ranked predictors from each random forest model and used Bayesian Information Criterion (BIC) to select
336 the best fit model for each epidemic metric, allowing each metric's regression model to include up to three
337 independent variables. This additional step of variable selection demonstrated that models with few
338 predictors fit the observed data relatively well (epidemic size, adjusted $R^2 = 0.69$; peak incidence, adj. R^2
339 $= 0.63$; effective R_t , adj. $R^2 = 0.65$; epidemic intensity, adj. $R^2 = 0.75$), except for subtype dominance (adj.
340 $R^2 = 0.48$) (Table 3). The set of variables retained after model selection were similar to those with high
341 importance rankings in random forest models and LASSO regression models, with the exception that H1
342 \log_2 titer distance, rather than H3 epitope distance, was included in the minimal models of effective R_t and
343 epidemic intensity.

344 Discussion

345
346 Antigenic drift between currently circulating influenza viruses and the previous season's viruses is
347 expected to confer increased viral fitness, leading to earlier, larger, or more severe epidemics. However,
348 prior evidence for the impact of antigenic drift on seasonal influenza outbreaks is mixed. Here, we
349 systematically compare experimental and sequence-based measures of A(H3N2) evolution in predicting
350 regional epidemic dynamics in the United States across 22 seasons, from 1997 to 2019. We also
351 consider the effects of other co-circulating influenza viruses, prior immunity, and vaccine-related
352 parameters, such as coverage and effectiveness, on A(H3N2) incidence. Our findings indicate that
353 evolution in both major surface proteins – hemagglutinin (HA) and neuraminidase (NA) – contributes to
354 variability in epidemic magnitude across seasons, though viral fitness appears to be secondary to subtype
355 interference in shaping annual outbreaks.

356
357 The first question of this study sought to determine which metrics of viral fitness have the strongest
358 relationships with A(H3N2) epidemic burden and timing. Among our set of candidate evolutionary
359 predictors, genetic distances based on broad sets of epitope sites (HA = 129 sites; NA = 223 epitope
360 sites) had the strongest, most consistent associations with A(H3N2) epidemic size, transmission rate,
361 severity, subtype dominance, and age-specific patterns. Increased epitope distance in both H3 and N2
362 correlated with larger epidemics and increased transmissibility, with univariate analyses finding H3
363 distance more strongly correlated with epidemic size, peak incidence, transmissibility, and excess
364 mortality, and N2 distance more strongly correlated with epidemic intensity (i.e., the “sharpness” of the
365 epidemic curve) and subtype dominance patterns. However, we note that minor differences in correlative
366 strength between H3 and N2 epitope distance are not necessarily biologically relevant and could be
367 attributed to noise in epidemiological or virological data or the limited number of influenza seasons in our
368 study. The fraction of ILI cases in children relative to adults was negatively correlated with N2 epitope
369 distance, consistent with the expectation that cases are more restricted to immunologically naïve children
370 in seasons with low antigenic novelty [7,78]. Regarding epidemic timing, the number of days from
371 epidemic onset to peak (a proxy for epidemic speed) decreased with N2 epitope distance, but other
372 measures of epidemic timing, such as peak week, onset week, and spatiotemporal synchrony across
373 HHS regions, were not significantly correlated with H3 or N2 antigenic change.

374
375 The local branching index (LBI) is traditionally used to predict the success of individual clades, with a high
376 LBI value indicating high viral fitness [35,62]. In our epidemiological analysis, low diversity of H3 or N2
377 LBI values, in the current or prior season, correlated with greater epidemic intensity, higher transmission
378 rates, and shorter seasonal duration. This outcome suggests that low LBI diversity is indicative of a rapid
379 selective sweep by one successful clade and that high LBI diversity is indicative of multiple co-circulating
380 clades with variable seeding times over the course of an epidemic. A caveat is that LBI estimation is more
381 sensitive to sequence sub-sampling schemes than strain-level measures. If an epidemic is very short and
382 intense (e.g., 1-2 months), a phylogenetic tree with our sub-sampling scheme (50 sequences per month)
383 may not incorporate enough sequences to capture the true diversity of LBI values in that season.

384

385 Positive associations between H3 antigenic drift and population-level epidemic burden are consistent with
386 previous observations from theoretical models [25,26,83]. For example, phylodynamic models of
387 punctuated antigenic evolution have reproduced key features of A(H3N2) phylogenetic patterns and case
388 dynamics, such as the sequential replacement of antigenic clusters, the limited standing diversity in HA
389 after a cluster transition, and higher incidence and attack rates in cluster transition years [25,26,83]. Our
390 results also corroborate empirical analyses of surveillance data [6,27,28,66] and forecasting models of
391 annual epidemics [29,30] that found direct, quantitative links between HA antigenic novelty and the
392 number of influenza cases or deaths in a season. Moving beyond the paradigm of antigenic clusters, Wolf
393 et al., 2010 and Bedford et al., 2014 demonstrated that smaller, year-to-year changes in H3 antigenic drift
394 also correlate with seasonal severity and incidence [6,27]. A more recent study did not detect an
395 association between antigenic drift and city-level epidemic size in Australia [31], though the authors used
396 a binary indicator to signify seasons with major HA antigenic transitions and did not consider smaller,
397 more gradual changes in antigenicity. While Lam and colleagues did not observe a consistent effect of
398 antigenic change on epidemic magnitude, they found a negative relationship between the cumulative prior
399 incidence of an antigenic variant and its probability of successful epidemic initiation in a city [31].

400
401 We did not observe a clear relationship between H3 receptor binding site (RBS) distance and epidemic
402 burden, even though single substitutions at these seven amino acid positions are implicated in major
403 antigenic transitions [68,84]. The outperformance of the RBS distance metric by a broader set of epitope
404 sites could be attributed to the tempo of antigenic cluster changes. A(H3N2) viruses are characterized by
405 both continuous and punctuated antigenic evolution, with transitions between antigenic clusters occurring
406 every 2 to 8 years [6,26,32,33,36,37,67,68,85]. Counting substitutions at only a few sites may fail to
407 capture more modest, gradual changes in antigenicity that are on a time scale congruent with annual
408 outbreaks. Further, a broader set of epitope sites may better capture the epistatic interactions that
409 underpin antigenic change in HA [86]. Although the 7 RBS sites were responsible for the majority of
410 antigenic phenotype in Koel et al.'s experimental study [68], their findings do not necessarily contradict
411 studies that found broader sets of sites associated with antigenic change. Mutations at other epitope sites
412 may collectively add to the decreased recognition of antibodies or affect viral fitness through alternate
413 mechanisms (e.g., compensatory or permissive mutations) [26,32,36,62,68,86-88].

414
415 A key result from our study is the direct link between NA antigenic drift and A(H3N2) incidence patterns.
416 Although HA and NA both contribute to antigenicity [20,89] and undergo similar rates of positive selection
417 [34], we expected antigenic change in HA to exhibit stronger associations with seasonal incidence, given
418 its immunodominance relative to NA [90]. H3 and N2 epitope distance were both moderately correlated
419 with epidemic size, peak incidence, and subtype dominance patterns, but, except for subtype dominance,
420 H3 epitope distance had higher variable importance rankings in random forest models and N2 epitope
421 distance was not retained after post-hoc model selection of top ranked random forest features. However,
422 N2 epitope distance but not H3 epitope distance was associated with faster epidemic speed and a greater
423 fraction of ILI cases in adults relative to children. Antigenic changes in H3 and N2 were independent
424 across the 22 seasons of our study, consistent with previous research [34,74,76]. Thus, the similar
425 predictive performance of HA and NA epitope distance for some epidemic metrics does not necessarily
426 stem from the coevolution of HA and NA.

427
428 HI log₂ titer distance was positively correlated with different measures of epidemic impact yet
429 underperformed in comparison to H3 and N2 epitope distances. This outcome was surprising given that
430 we expected our method for generating titer distances to produce more realistic estimates of immune
431 cross-protection between viruses than epitope-based measures. Our computational approach for inferring
432 HI phenotype dynamically incorporates newer titer measurements and assigns antigenic weight to
433 phylogenetic branches rather than fixed sequence positions [35,63], while our method for calculating
434 epitope distance assumes that the contributions of specific sites to antigenic drift are constant through
435 time, even though beneficial mutations previously observed at these sites are contingent on historical
436 patterns of viral fitness and host immunity [26,35,62]. HI titer measurements have been more useful than

437 epitope substitutions in predicting future A(H3N2) viral populations [35] and vaccine effectiveness [91],
438 with the caveat that these targets are more proximate to viral evolution than epidemic dynamics.
439

440 HI titer measurements may be more immunologically relevant than epitope-based measures, yet several
441 factors could explain why substitutions at epitope sites outperformed HI titer distances in epidemiological
442 predictions. First, epitope distances may capture properties that affect viral fitness (and in turn outbreak
443 intensity) but are unrelated to immune escape, such as intrinsic transmissibility, ability to replicate, or
444 epistatic interactions. A second set of factors concern methodological issues associated with HI assays.
445 The reference anti-sera for HI assays are routinely produced in ferrets recovering from their first influenza
446 virus infection. Most humans are infected by different influenza virus strains over the course of their
447 lifetimes, and one's immune history influences the specificity of antibodies generated against drifted
448 influenza virus strains [92-95]. Thus, human influenza virus antibodies, especially those of adults, have
449 more heterogeneous specificities than anti-sera from immunologically naïve ferrets [92].
450

451 A related methodological issue is that HI assays disproportionately measure anti-HA antibodies that bind
452 near the receptor binding site and, similar to the RBS distance metric, may capture only a partial view of
453 the antigenic change occurring in the HA protein [31,78,96,97]. A recent study of longitudinal serological
454 data found that HI titers are a good correlate of protective immunity for children, while time since infection
455 is a better predictor of protection for adults [97]. This outcome is consistent with the concept of antigenic
456 seniority, in which an individual's first exposure to influenza virus during childhood leaves an
457 immunological "imprint", and exposure to new strains "back boosts" one's antibody response to strains of
458 the same subtype encountered earlier in life [78,98,99]. Ranjeva et al.'s study and others suggest that
459 human influenza virus antibodies shift focus from the HA head to other more conserved epitopes as
460 individuals age [78,96]. Given that HI assays primarily target epitopes adjacent to the RBS, HI assays
461 using ferret or human serological data are not necessarily suitable for detecting the broader immune
462 responses of adults. A third explanation for the underperformance of HI titers concerns measurement
463 error. Recent A(H3N2) viruses have reduced binding efficiency in HI assays, which can skew estimates of
464 immune cross-reactivity between viruses [100]. These combined factors could obfuscate the relationship
465 between the antigenic phenotypes inferred from HI assays and population-level estimates of A(H3N2)
466 incidence.
467

468 Novel antigenic variants are expected to have higher infectivity in immune populations, leading to earlier
469 epidemics and more rapid geographic spread [19], but few studies have quantitatively tied antigenic drift
470 to epidemic timing or geographic synchrony. Previous studies of pneumonia and influenza-associated
471 mortality observed greater severity or geographic synchrony in seasons with major antigenic transitions
472 [21,24]. A more recent Australian study of lab-confirmed cases also noted greater spatiotemporal
473 synchrony during seasons in which novel H3 antigenic variants emerged, although their assessment was
474 based on virus typing alone (i.e., influenza A or B) [17]. A subsequent Australian study with finer-
475 resolution data on subtype incidence and variant circulation determined that more synchronous epidemics
476 were not associated with drifted A(H3N2) strains [31], and a US-based analysis of ILI data also failed to
477 detect a relationship between HA antigenic cluster transitions and geographic synchrony [16]. In our
478 study, the earliest epidemics tended to occur in seasons with transitions between H3 antigenic clusters
479 (e.g., the emergence of the FU02 cluster in 2003-2004) or vaccine mismatches (e.g., N2 mismatch in
480 1999-2000, H3 mismatch in 2014-2015) [32,74,101], but there was not a statistically significant correlation
481 between antigenic change and earlier epidemic onsets or peaks. Regarding epidemic speed, the length of
482 time from epidemic onset to peak decreased with N2 epitope distance but not H3 epitope distance. The
483 relationship between antigenic drift and epidemic timing may be ambiguous because external seeding
484 events or climatic factors, such as temperature and absolute humidity, are more important in driving
485 influenza seasonality and the onsets of winter epidemics [7,10-14,16]. Alternatively, the resolution of our
486 epidemiological surveillance data (HHS regions) may not be granular enough to detect a signature of
487 antigenic drift in epidemic timing, though studies of city-level influenza dynamics were also unable to
488 identify a clear relationship [16,31].
489

490 After exploring individual correlations between evolutionary indicators and annual epidemics, we
491 considered the effects of influenza A(H1N1) incidence and B incidence on A(H3N2) virus circulation
492 within a season. We detected strong negative associations between A(H1N1) incidence and A(H3N2)
493 epidemic size, peak incidence, transmissibility, and excess mortality, consistent with previous animal,
494 epidemiological, phylodynamic, and theoretical studies that found evidence for cross-immunity between
495 IAV subtypes [53-55,57,59,102]. For example, individuals recently infected with seasonal influenza A
496 viruses are less likely to become infected during subsequent pandemic waves [52,53,102-104], and the
497 early circulation of one influenza virus type or subtype is associated with a reduced total incidence of the
498 other type/subtypes within a season [31,57]. Due to the shared evolutionary history of their internal genes
499 [79], pre-2009 seasonal A(H1N1) viruses may impact A(H3N2) virus circulation to a greater extent than
500 A(H1N1)pdm09 viruses, which have a unique combination of genes that were not identified in animals or
501 humans prior to 2009 [81,105]. We observed similar relationships between A(H3N2) epidemic metrics
502 and A(H1N1) incidence during pre- and post-2009 pandemic seasons, with slightly stronger correlations
503 observed during the pre-2009 period. However, given the small sample size (12 pre-2009 seasons and 9
504 post-2009 seasons), we cannot fully answer this question.

505
506 In our study, univariate correlations between A(H1N1) and A(H3N2) incidence were more pronounced
507 than those observed between A(H3N2) incidence and evolutionary indicators, and A(H1N1) epidemic size
508 was the highest ranked feature by random forest models predicting epidemic size and peak incidence.
509 Consequently, interference between the two influenza A subtypes may be more impactful than viral
510 evolution in determining the size of annual A(H3N2) outbreaks. Concerning epidemic timing, we did not
511 detect a relationship between A(H3N2) antigenic change and the relative timing of A(H3N2) and A(H1N1)
512 cases; specifically, A(H3N2) incidence did not consistently lead A(H1N1) incidence in seasons with
513 greater H3 or N2 antigenic change. Overall, we did not find any indication that influenza B incidence
514 affects A(H3N2) epidemic burden or timing, which is not unexpected, given that few T and B cell epitopes
515 are shared between the two virus types [106].

516
517 Lastly, we used random forest models and multivariable linear regression models to assess the relative
518 importance of viral evolution, prior population immunity, co-circulation of other influenza viruses, and
519 vaccine-related parameters in predicting regional A(H3N2) epidemic dynamics. We chose conditional
520 inference random forest models as our primary method of variable selection because several covariates
521 were collinear, relationships between some predictors and target variables were nonlinear, and our goal
522 was inferential rather than predictive. We performed leave-one-season-out cross-validation to tune each
523 model, but, due to the limited number of seasons in our dataset, we were not able to test predictive
524 performance on an independent test set. With the caveat that models were likely overfit to historical data,
525 random forest models produced accurate predictions of regional epidemic size, peak incidence, and
526 subtype dominance patterns, while predictions of epidemic intensity and transmission rates were less
527 exact. The latter two measures could be more closely tied to climatic factors, the timing of influenza case
528 importations from abroad, or mobility patterns [7,13,14,16] or they may be inherently more difficult to
529 predict because their values are more constrained. Random forest models tended to underpredict
530 epidemic burden in seasons with major antigenic transitions, particularly the SY97 seasons (1998-1999,
531 1999-2000) and the FU02 season (2003-2004), potentially because antigenic jumps of these magnitudes
532 were infrequent during our 22-season study period. An additional step of post-hoc model selection
533 demonstrated that models with only three covariates could also produce accurate fits to observed
534 epidemiological data.

535
536 Our study is subject to several limitations, specifically regarding geographic resolution and data
537 availability. First, our analysis is limited to one country with a temperate climate and its findings
538 concerning interactions between A(H3N2), A(H1N1), and type B viruses may not be applicable to tropical
539 or subtropical countries, which experience sporadic epidemics of all three viruses throughout the year
540 [107]. Second, our measure of population-level influenza incidence is derived from regional CDC
541 outpatient data because those data are publicly available starting with the 1997-1998 season. State level
542 outpatient data are not available until after the 2009 A(H1N1) pandemic, and finer resolution data from

543 electronic health records are accessible in theory but not in the public domain. Access to ILI cases
544 aggregated at the state or city level, collected over the course of decades, would increase statistical
545 power and enable us to add more location-specific variables to our analysis, such as climatic and
546 environmental factors. A third limitation is that we measured influenza incidence by multiplying the rate of
547 influenza-like illness by the percentage of tests positive for influenza, which does not completely eliminate
548 the possibility of capturing the activity of other co-circulating respiratory pathogens [11]. Surveillance data
549 based on more specific diagnosis codes would ensure the exclusion of patients with non-influenza
550 respiratory conditions. Fourth, our data on the age distribution of influenza cases were derived from ILI
551 encounters across four broad age groups and did not include test positivity status, virus type/subtype, or
552 denominator information. Despite the coarseness of these data, we found statistically significant
553 correlations in the expected directions between N2 antigenic change and the fraction of cases in children
554 relative to adults. Lastly, a serological assay exists for NA, but NA titer measurements are not widely
555 available because the assay is labor-intensive and inter-lab variability is high. Thus, we could not test the
556 performance of NA antigenic phenotype in predicting epidemic dynamics.

557
558 Beginning in early 2020, non-pharmaceutical interventions (NPIs), including lockdowns, school closures,
559 physical distancing, and masking, were implemented in the United States and globally to slow the spread
560 of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the COVID-
561 19 pandemic. These mitigation measures disrupted the transmission of seasonal influenza viruses and
562 other directly-transmitted respiratory viruses throughout 2020 and 2021 [108-113], and population
563 immunity to influenza is expected to have decreased substantially during this period of low circulation
564 [114,115]. COVID-19 NPIs relaxed during 2021 and 2022, and co-circulation of A(H3N2) and
565 A(H1N1)pdm09 viruses in the United States resumed during the 2022-2023 influenza season. Our study
566 concludes with the 2018-2019 season, and thus it is unclear whether our modeling approach would be
567 useful in projecting seasonal burden during the post-pandemic period, without an additional component to
568 account for COVID-19-related perturbations to influenza transmission. Further studies will need to
569 determine whether ecological interactions between influenza viruses have changed or if the effects of
570 viral evolution and subtype interference on seasonal outbreaks are different in the post-pandemic period.

571
572 In conclusion, relationships between A(H3N2) antigenic drift, epidemic impact, and age dynamics are
573 moderate, with genetic distances based on broad sets of H3 and N2 epitope sites having greater
574 predictive power than serology-based antigenic distances for the timeframe analyzed. Influenza
575 epidemiological patterns are consistent with increased population susceptibility in seasons with high
576 antigenic novelty, and our study is the first to link NA antigenic drift to epidemic burden, timing, and the
577 age distribution of cases. It is well established that anti-HA and anti-NA antibodies are independent
578 correlates of immunity [45,47-49,116-118], and the influenza research community has advocated for NA-
579 based vaccines [39,119]. The connection between NA drift and seasonal incidence further highlights the
580 importance of monitoring evolution in both HA and NA to inform vaccine strain selection and epidemic
581 forecasting efforts. Although antigenic change in both HA and NA was correlated with epidemic dynamics,
582 ecological interactions between influenza A subtypes appear to be more influential than viral evolution in
583 determining the intensity of annual A(H3N2) epidemics. The aim of our study was to retrospectively
584 assess the potential drivers of annual A(H3N2) epidemics, yet we cautiously suggest that one could
585 project the size or intensity of future epidemics based on sequence data and A(H1N1)pdm09 incidence
586 alone [27,57].

587 588 **Methods**

589 Unless otherwise noted, data processing and statistical analyses were performed using R version 4.3.0.

590 **Influenza epidemic timing and burden**

591 ***Influenza-like illness and virological surveillance data***

592 We obtained weekly epidemiological and virological data for influenza seasons 1997-1998 to 2018-2019,
593 at the U.S. HHS region level [120]. We defined influenza seasons as calendar week 40 in a given year to
594 calendar week 20 in the following year, with the exception of the 2008-2009 season, which ended in 2009
595 week 16 due to the emergence of the A(H1N1)pdm09 virus [57].

596 We extracted syndromic surveillance data for the ten HHS regions from the U.S. Outpatient Influenza-like
597 Illness Surveillance Network (ILINet) [120]. ILINet consists of approximately 3,200 sentinel outpatient
598 healthcare providers throughout the United States that report the total number of consultations for any
599 reason and the number of consultations for influenza-like illness (ILI) every week. ILI is defined as fever
600 (temperature of 100°F [37.8°C] or greater) and a cough and/or a sore throat. The indicator is based on
601 the weekly proportion of outpatient consultations for influenza-like illness and is available weighted or
602 unweighted by regional population size. The number of ILI encounters by age group are also provided (0-
603 4, 5-24, 25-64, and ≥65), but these data are not weighted by total encounters or population size.

604 Data on weekly influenza virus type and subtype circulation were obtained from the US CDC's World
605 Health Organization (WHO) Collaborating Center for Surveillance, Epidemiology and Control of Influenza
606 [121]. We estimated the weekly number of respiratory samples testing positive for influenza A(H1N1),
607 A(H1N1)pdm09, A(H3N2), or B at the HHS region level (see Supplementary Methods for details on data
608 processing). We defined influenza A subtype dominance in each season based on the proportion of
609 influenza A virus (IAV) positive samples typed as A(H3N2). We defined seasons as A(H3N2) or A(H1N1)
610 or A(H1N1)pdm09 dominant when ≥70% of IAV positive samples were typed as one IAV subtype and co-
611 dominant when one IAV subtype comprised 50-69% of IAV positive samples.

612 For each HHS region, we estimated weekly incidences of influenza A(H3N2), A(H1N1), and B by
613 multiplying the percentage of influenza-like illness among outpatient visits, weighted by regional
614 population, with the percentage of respiratory samples testing positive for a particular type/subtype
615 [57,77]. We combined pre-2009 seasonal A(H1N1) and A(H1N1)pdm09 viruses as A(H1N1) and the
616 Victoria and Yamagata lineages of influenza B as influenza B. ILI x percent positive (ILI+) is considered a
617 robust estimate of influenza activity and has been used in multiple prior modeling studies
618 [6,18,57,77,122]. We used linear interpolation to estimate missing values for time spans of up to four
619 consecutive weeks.

620 The emergence of A(H1N1)pdm09 in 2009 altered influenza testing and reporting patterns. We adjusted
621 weekly incidences for differences in reporting rates between the pre-2009 pandemic period – defined as
622 1997 week 40 to 2009 week 17 – and the post-pandemic period – defined as the weeks after 2010 week
623 33. For each region, we scaled pre-pandemic incidences by the ratio of mean weekly ILI+ (for all influenza
624 type/subtypes combined) in the post-pandemic period to that of the pre-pandemic period. Incidences for
625 HHS Region 10 were not adjusted for pre- and post-pandemic reporting because surveillance data for this
626 region were not available before 2009. To account for differences in reporting rates across HHS regions,
627 we next scaled each region's type/subtype incidences by its mean weekly ILI+ for the entire study period.
628 Scaled incidences were used in all downstream analyses of epidemic burden and timing.

629 ***Epidemic burden and timing***

630 *Epidemic burden:* We considered three complementary indicators of epidemic burden, separately for
631 each influenza type/subtype, HHS region, and season. We defined *peak incidence* as the maximum
632 weekly scaled incidence and *epidemic size* as the cumulative weekly scaled incidence. We also
633 estimated *epidemic intensity* based on a method previously developed to study variation in the shape
634 (i.e., sharpness) of influenza epidemics across US cities [123]. Epidemic intensity was based on the
635 inverse Shannon entropy of the weekly incidence distribution. Epidemic intensity increases when
636 incidence is more concentrated in particular weeks and decreases when incidence is more evenly spread
637 across weeks.

638 Specifically, we defined the incidence distribution p_{ij} as the fraction of influenza incidence in season j that
639 occurred during week i in a given region, and epidemic intensity v_j as the inverse of the Shannon entropy
640 of the incidence distribution:

$$641 \quad v_j = \left(- \sum_i p_{ij} \ln p_{ij} \right)^{-1}$$

642 Epidemic intensity values were normalized to fall between 0 and 1.

643 *Transmission intensity:* For each region, we used the Epidemia R package to model annual A(H3N2)
644 epidemics and to estimate time-varying (instantaneous) reproduction numbers, effective R_t [124,125](see
645 Supplementary Methods for model details). Epidemia implements a semi-mechanistic Bayesian approach
646 using the probabilistic programming language Stan [126].

647 To generate seasonal indicators of transmission intensity, we extracted posterior draws of daily R_t
648 estimates for each region and season, calculated the median value for each day, and averaged daily
649 median values by epidemic week. For each region and season, we averaged R_t estimates from the
650 weeks spanning epidemic onset to epidemic peak (*initial R_t*) and averaged the two highest R_t estimates
651 (*maximum R_t*). Initial R_t and maximum R_t produced qualitatively similar results in downstream analyses;
652 we opted to report results for maximum R_t .

653 *Excess pneumonia and influenza deaths attributable to A(H3N2):* To measure the epidemic severity each
654 season, we obtained estimates of seasonal excess mortality attributable to influenza A(H3N2) from
655 Hansen et al., 2022 [127]. Excess mortality is a measure of the mortality burden of a given pathogen in
656 excess of a seasonally adjusted baseline, obtained by regressing weekly deaths from broad disease
657 categories against indicators of influenza virus circulation. Hansen et al. used pneumonia and influenza
658 (P&I) excess deaths, which is considered the most specific indicator of influenza burden [128]. Deaths
659 with a mention of P&I (ICD 10: J00-J18) were aggregated by week and age group (<1, 1-4, 5-49, 50-64,
660 and ≥ 65) for 1998-2018. Age-specific generalized linear models were fit to observed weekly P&I death
661 rates, while accounting for influenza and respiratory syncytial virus (RSV) activity and seasonal and
662 temporal trends. Hansen et al. estimated the weekly national number of excess A(H3N2)-associated
663 deaths by subtracting the baseline death rate expected in the absence of A(H3N2) circulation (A(H3N2)
664 model terms set to zero) from the observed P&I death rate. We summed the number of excess A(H3N2)
665 deaths per 100,000 people from October to May to obtain seasonal age-specific estimates.

666 *Epidemic onset and peak timing:* We estimated the regional onsets of A(H1N1), A(H1N1)pdm09,
667 A(H3N2), and B epidemics each season by fitting piecewise linear models to subtype-specific incidence
668 curves from week 30 to the first week of maximum incidence. We did not estimate epidemic onsets for
669 regions with insufficient signal, which we defined as fewer than three weeks of consecutive incidence
670 and/or greater than 30% of weeks with missing data in a particular season. The timing of the changepoint
671 in incidence represents epidemic establishment (i.e., sustained transmission) rather the timing of
672 influenza introduction or arrival [16]. We were able to estimate A(H3N2) onset timing for most seasons,
673 except for three A(H1N1) dominant seasons: 2000-2001 (0 regions), 2002-2003 (3 regions), and 2009-
674 2010 (0 regions). We defined epidemic peak timing as the first week of maximum incidence. To measure
675 spatiotemporal synchrony, we calculated seasonal variation (standard deviation, s.d.) in regional onset
676 and peak timing [19,27]. To measure the speed of viral spread, we calculated the number of days
677 between onset and peak and seasonal duration (the number of weeks with non-zero incidence) for each
678 region. As a sensitivity analysis, we used wavelets to estimate timing differences between A(H3N2),
679 A(H1N1), A(H1N1)pdm09, and B epidemics (see Supplementary Methods).

680 *Age patterns:* We calculated the seasonal proportion of ILI encounters in each age group (0-4 years, 5-24
681 years, 25-64 years, and ≥ 65 years). Data for more narrow age groups are available after 2009, but we
682 chose these four categories to increase the number of seasons in our analysis.

683 **Influenza vaccination coverage and A(H3N2) vaccine effectiveness**

684 Influenza vaccination coverage and effectiveness vary between years and would be expected to affect
685 the population impact of seasonal outbreaks, and in turn our epidemiologic indicators. We obtained
686 seasonal estimates of national vaccination coverage for adults 18-49 years and adults ≥ 65 years from
687 studies utilizing vaccination questionnaire data collected by the National Health Interview Survey [129-
688 135]. We did not consider the effects of vaccination coverage in children, due to our inability to find
689 published estimates for most influenza seasons in our study.

690 We obtained seasonal estimates of adjusted A(H3N2) vaccine effectiveness (VE) from 32 observational
691 studies [136-167]. Most of these studies had case-control test-negative designs ($N = 30$) and took place
692 in North America ($N = 25$) or Europe ($N = 6$). When possible, we limited VE estimates to those for healthy
693 adults or general populations. When multiple VE studies were available for a given season, we calculated
694 mean VE as the weighted average of m different VE point estimates:

$$695 \frac{\sum_{i=1}^m \delta_{VE_i}^{-1/2} VE_i}{\sum_{i=1}^m \delta_{VE_i}^{-1/2}}$$

696 Wherein δ_{VE} denotes the width of the 95% confidence interval (CI) for VE_i [91].

697 The 95% CI for the weighted mean VE was calculated as:

$$698 \frac{1}{m} \sqrt{\sum_{i=1}^m (\delta_{VE_i})^2}$$

699 **Correlations among epidemic metrics**

700 We used Spearman's correlation coefficients to measure pairwise relationships between A(H3N2)
701 epidemiological indicators. We adjusted P-values for multiple testing using the Benjamini and Hochberg
702 method [168].

703 **Indicators of influenza A(H3N2) evolution**

704 We considered multiple indicators of influenza evolution based on genetic and phenotypic (serologic)
705 data, separately for HA and NA.

706 **HA and NA sequence data**

707 We downloaded all H3 sequences and associated metadata from the Global Initiative on Sharing Avian
708 Influenza Data (GISAID) EpiFlu database [60]. We focused our analysis on complete H3 sequences that
709 were sampled between January 1, 1997, and October 1, 2019. We prioritized viruses with corresponding
710 HI titer measurements provided by the WHO Global Influenza Surveillance and Response System
711 (GISRS) Collaborating Centers and excluded all egg-passaged viruses and sequences with ambiguous
712 year, month, and day annotations. To account for variation in sequence availability across global regions,
713 we subsampled the selected sequences five times to representative sets of 50 viruses per month, with
714 preferential sampling for North America. Each month 25 viruses (when available) were selected from
715 North America, with even sampling across nine other global regions (Africa, Europe, China, South Asia,
716 Japan and Korea, Oceania, South America, Southeast Asia, and West Asia) for the remaining 25 viruses.
717 To ensure proper topology early in the phylogeny, we included reference strains that had been collected
718 no earlier than 5 years prior to January 1, 1997. The resultant sets of H3 sequences included 10,088 to
719 10,090 sequences spanning December 25, 1995 – October 1, 2019.

720 As with the H3 analysis, we downloaded all N2 sequences and associated metadata from GISAID and
721 selected complete N2 sequences that were sampled between January 1, 1997, and October 1, 2019. We
722 excluded all sequences with ambiguous year, month, and day annotations, forced the inclusion of
723 reference strains collected no earlier than 5 years prior to January 1, 1997, and compiled five replicate
724 subsampled datasets with preferential sampling for North America (9,007 to 9,009 sequences; June 8,
725 1995 – October 1, 2019).

726 ***HA serologic data***

727 Hemagglutination inhibition (HI) measurements from ferret sera were provided by WHO GISRS
728 Collaborating Centers in London, Melbourne, Atlanta, and Tokyo. We converted these raw two-fold
729 dilution measurements to \log_2 titer drops normalized by the corresponding \log_2 autologous measurements
730 [35,63].

731 Although a phenotypic assay exists for NA, NA inhibiting antibody titers are not routinely measured for
732 influenza surveillance. Therefore, we could not include a phenotypic marker of NA evolution in our study.

733 ***Phylogenetic inference***

734 For each set of H3 and N2 sequences, we aligned sequences with the augur align command [169] and
735 MAFFT v7.407 [170]. We inferred initial phylogenies with IQ-TREE v1.6.10 [171]. To reconstruct time-
736 resolved phylogenies, we applied TreeTime v0.5.6 [172] with the augur refine command [173].

737 ***Viral fitness metrics***

738 Following Huddleston et al., 2020 [35], we defined the following fitness metrics for each influenza season:

739 Antigenic drift: We estimated antigenic drift for each H3 strain using either genetic or serologic data. We
740 implemented three sequence-based metrics based on substitutions at putative epitope sites: 129 sites in
741 HA1 [21,64,66,67,174], 7 sites adjacent to the receptor-binding site (RBS) [68], and 34 sites in the HA
742 stalk [70], hereon *HA epitope distance*, *HA RBS distance*, and *HA stalk footprint distance*. To estimate
743 antigenic drift with hemagglutination inhibition (HI) titer data, hereon *HI \log_2 titer distance*, we applied the
744 phylogenetic tree model from Neher et al., 2016 [63] to the H3 phylogeny and available HI data for its
745 sequences. The tree model estimates the antigenic drift per branch in units of \log_2 titer change.

746 To estimate N2 antigenic drift, we implemented two sequence-based metrics that count substitutions at
747 putative epitope sites in the NA head: 223 sites [34] or 53 sites [69], hereon *NA epitope distance*.

748 Mutational load: To estimate mutational load for each H3 and N2 strain, an inverse proxy of viral fitness
749 [61], we implemented metrics that count substitutions at putative non-epitope sites in HA (N = 200) and
750 NA (N = 246), hereon *HA non-epitope distance* and *NA non-epitope distance*. Mutational load metrics
751 produce higher values for strains that are less fit compared to previously circulating strains.

752 Clade growth: We estimated the seasonal growth of H3 clades and N2 clades with the local branching
753 index (LBI) [62]. To calculate LBI for each H3 and N2 strain, we applied the LBI heuristic algorithm as
754 originally described by Neher et al., 2014 [62] to H3 and N2 phylogenetic trees, respectively. We set the
755 neighborhood parameter, τ , to 0.4 and only considered viruses sampled between the current season t
756 and the previous season $t - 1$ as contributing to recent clade growth in the current season t . To estimate
757 the diversity of clade growth rates in each season, we binned LBI values by units of 2 into 10 categories
758 ((0-2],[2-4], (4-6], (6-8], (8-10], (10-12],[12-14], (14-16],[16-18], (18-20]) and estimated the Shannon
759 entropy of LBI categories. Here, the Shannon entropy [175] considers both the richness and relative
760 abundance of viral clades with different growth rates and is calculated as follows:

761

$$H' = - \sum_i p_i \ln p_i$$

762 wherein p_i is the proportion of LBI values belonging to the i th bin.

763 ***Antigenic and genetic distance relative to prior seasons***

764 We estimated genetic and antigenic distances between influenza viruses circulating in consecutive
765 seasons by calculating the mean distance between viruses circulating in the current season t and viruses
766 circulating during the prior season ($t - 1$ year; one season lag) or two prior seasons ago ($t - 2$ years; two
767 season lag). Seasonal genetic and antigenic distances are greater when currently circulating strains are
768 more antigenically distinct from previously circulating strains. We used Spearman's correlation
769 coefficients to measure pairwise relationships between scaled H3 and N2 evolutionary indicators. We
770 adjusted P-values for multiple testing using the Benjamini and Hochberg method [168].

771 **Univariate relationships between viral fitness, (sub)type interference and A(H3N2) epidemic 772 impact**

773 We measured univariate associations between national indicators of A(H3N2) viral fitness and regional
774 A(H3N2) epidemic parameters – peak incidence, epidemic size, effective R_t , epidemic intensity, subtype
775 dominance, excess P&I deaths, onset timing, peak timing, spatiotemporal synchrony, the number of
776 weeks from onset to peak, and seasonal duration. We first measured Spearman correlation coefficients
777 between pairs of scaled fitness indicators and epidemic metrics using 1000 bootstrap replicates of the
778 original dataset (1000 samples with replacement).

779 Next, we fit regression models with different distribution families (Gaussian or Gamma) and link functions
780 (identity, log, or inverse) to observed data and used Bayesian information criterion (BIC) to select the best
781 fit model, with lower BIC values indicating a better fit to the data. For subtype dominance, epidemic
782 intensity, and age-specific proportions of ILI cases, we fit Beta regression models with logit links. For
783 each epidemic metric, we fit the best-performing regression model to the resampled dataset. To measure
784 the effects of sub(type) interference on A(H3N2) epidemics, the same approach was applied to measure
785 the univariate relationships between A(H1N1) or B epidemic size and A(H3N2) peak incidence, epidemic
786 size, effective R_t , epidemic intensity, and excess mortality. As a sensitivity analysis, we tested univariate
787 relationships between A(H3N2) epidemic metrics and A(H1N1) epidemic size during pre-2009 seasons
788 (seasonal A(H1N1) viruses) and post-2009 seasons (A(H1N1)pdm09 viruses) separately.

789 All predictors were centered and scaled prior to measuring Spearman's correlations or fitting regression
790 models.

791 **Selecting relevant predictors of A(H3N2) epidemic impact**

792 Next, we explored multivariable approaches that would shed light on the potential mechanisms driving
793 annual epidemic impact. Considering that we had many predictors and relatively few observations (22
794 seasons x 9-10 HHS regions), several covariates were collinear, and our goal was explicative rather than
795 predictive, we settled on methods that tend to select few covariates.
796
797
798

799 We first used conditional inference random forest models to select relevant predictors of A(H3N2)
800 epidemic size, peak incidence, effective R_t , epidemic intensity, and subtype dominance (party and caret
801 R packages) [176-179]. Candidate predictors included viral fitness indicators: genetic and antigenic
802 distance from previously circulating strains and the Shannon entropy of H3 and N2 LBI values in the
803 current and prior season; proxies for prior natural immunity: A(H3N2) epidemic size in the prior season,
804 influenza A(H1N1) epidemic size and B epidemic size in the current and prior seasons, and the dominant
805 sub(type) in the prior season [12]; and vaccine-related parameters: national adult vaccination coverage in

806 the current and previous season, A(H3N2) vaccine effectiveness in the current and previous season, and
807 H3 and N2 epitope distances between circulating A(H3N2) viruses in the United States and the A(H3N2)
808 vaccine strain in the same season. We did not conduct variable selection analysis for excess A(H3N2)
809 mortality due to data limitations (one national estimate per season). Metrics related to epidemic timing
810 were also excluded from this analysis because we found weak or non-statistically significant associations
811 with most of the candidate evolutionary predictors in univariate analyses.

812
813 We created each forest by generating 3,000 regression trees from 10 repeats of a leave-one-season-out
814 (jackknife) cross-validated sample of the data. Due to the small size of our dataset, evaluating the
815 predictive accuracy of random forest models on a quasi-independent test set produced unstable
816 estimates. Consequently, we included all data in the training set and report root mean squared error
817 (RMSE) and R^2 values from the best tuned model. We used permutation importance ($N = 50$
818 permutations) to estimate the relative importance of each predictor in determining model outcomes.
819 Permutation importance is the decrease in prediction accuracy when a single feature (predictor) is
820 randomly permuted, with larger values indicating more important variables. Because our features were
821 collinear, we used conditional permutation importance to compute feature importance scores, rather than
822 the standard marginal procedure [177,178,180,181].

823
824 As an alternative method for variable selection, we performed LASSO regression on the same cross-
825 validated dataset and report RMSE and R^2 values from the best tuned model (glmnet and caret R
826 packages)[179,182]. Unlike random forest models, this approach assumes linear relationships between
827 predictors and the target variable. LASSO models (L1 penalty) are more restrictive than ridge models (L2
828 penalty) and elastic net models (combination of L1 and L2 penalties) and will arbitrarily select one
829 variable from a set of collinear variables.

830
831 To further reduce the set of predictors for each epidemic metric, we performed model selection with linear
832 regression models that considered all combinations of the top 10 ranked predictors from conditional
833 inference random forest models. Candidate models were limited to three independent variables, and
834 models were compared using BIC. We did not include HHS region or season as fixed or random effects in
835 these models because these variables either did not improve model fit (region) or caused convergence
836 issues (season).

837
838 All predictors were centered and scaled prior to fitting random forest or regression models.

839 **Data availability**

840
841
842 Sequence data are available from GISAID using accession ids provided in Supplementary file 1. Source
843 code for phylogenetic analyses, inferred HI titers from serological measurements, and evolutionary fitness
844 measurements are available in the GitHub repository <https://github.com/blab/perofsky-ili-antigenicity>. The
845 five replicate trees for HA and NA can be found at <https://nextstrain.org/groups/blab/> under the keyword
846 "perofsky-ili-antigenicity". Epidemiological data, datasets combining seasonal evolutionary fitness
847 measurements and epidemic metrics, and source code for calculating epidemic metrics and performing
848 statistical analyses are available in the GitHub repository
849 https://github.com/aperofsky/H3N2_Antigenic_Epi. Raw serological measurements are restricted from
850 public distribution by previous data sharing agreements.

851 **Acknowledgements**

852
853
854 We thank the Influenza Division at the US Centers for Disease Control and Prevention, the Victorian
855 Infectious Diseases Reference Laboratory at the Australian Peter Doherty Institute for Infection and
856 Immunity, the Influenza Virus Research Center at the Japan National Institute of Infectious Diseases, the
857 Crick Worldwide Influenza Centre at the UK Francis Crick Institute for sharing HI titer data. We gratefully
858 acknowledge the authors, originating and submitting laboratories of the sequences from the GISAID

859 EpiFlu Database on which this research is based (listed in Appendix 1). We thank members of the
860 Fogarty International Center's Division of International Epidemiology and Population Studies (DIEPS) and
861 the Bedford Lab for useful discussions.

862

863 **Funding information**

864 ACP, CH, and CV were supported by the in-house research division of the Fogarty International Center,
865 US National Institutes of Health. ACP was supported by the NSF Infectious Disease Evolution Across
866 Scales (IDEAS) Research Collaboration Network. JH was supported by NIH NIAID awards F31 AI140714
867 and R01 AI165821. The work done at the Crick Worldwide Influenza Centre was supported by the Francis
868 Crick Institute receiving core funding from Cancer Research UK (FC001030), the Medical Research
869 Council (FC001030) and the Wellcome Trust (FC001030). SF, KN, NK, SW and HH were supported by
870 the Ministry of Health, Labour and Welfare, Japan (10110400 and 10111800). SW was supported by the
871 Japan Agency for Medical Research and Development (JP22fk0108118 and JP23fk0108662). The WHO
872 Collaborating Centre for Reference and Research on Influenza is supported by the Australia Government
873 Department of Health and Aged Care. The Melbourne WHO Collaborating Centre for Reference and
874 Research on Influenza is supported by the Australian Government Department of Health. Influenza virus
875 work in the Krammer laboratory was partially supported by the NIAID Centers of Excellence for Influenza
876 Research and Surveillance (CEIRS) contract HHSN272201400008C, NIAID Centers of Excellence for
877 Influenza Research and Response (CEIRR) contract 75N93021C00014 (FK), and NIAID CIVIC contract
878 (75N93019C00051). TB was supported by NIH awards NIGMS R35 GM119774 and NIAID R01
879 AI127893. TB is an Investigator of the Howard Hughes Medical Institute. Funding sources were not
880 involved in study design, data collection and interpretation, or the decision to submit the work for
881 publication.

882

883 **Disclaimer**

884 The conclusions of this study do not necessarily represent the views of the National Institutes of Health,
885 the Centers for Disease Control and Prevention, or the US government.

886

887 **Author contributions**

888 Amanda C Perofsky: Conceptualization, Data curation, Software, Formal analysis, Funding acquisition,
889 Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration,
890 Writing - review and editing; John Huddleston: Data curation, Software, Formal Analysis, Validation,
891 Investigation, Visualization, Methodology, Writing - review and editing; Chelsea Hansen: Data curation,
892 Software, Formal Analysis, Investigation, Writing - review and editing; John R Barnes, Thomas Rowe,
893 Xiyun Xu, Rebecca Kondor, David E Wentworth, Nicola Lewis, Lynne Whittaker, Burcu Ermetal, Ruth
894 Harvey, Monica Galiano, Rodney Stuart Daniels, John W McCauley, Seiichiro Fujisaki, Kazuya
895 Nakamura, Noriko Kishida, Shinji Watanabe, Hideki Hasegawa, Sheena G Sullivan, Ian Barr, Kanta
896 Subbarao: Resources, Investigation, Methodology, Writing - review and editing; Florian Krammer: Data
897 curation, Resources, Investigation, Funding acquisition, Writing - review and editing; Trevor Bedford:
898 Conceptualization, Resources, Software, Supervision, Methodology, Project administration, Funding
899 acquisition; Cécile Viboud: Conceptualization, Resources, Supervision, Methodology, Project
900 administration, Funding acquisition, Writing - review and editing

901

902 **Competing interests**

903 The WHO Collaborating Centre for Reference and Research on Influenza in Melbourne has a
904 collaborative research and development agreement (CRADA) with CSL Seqirus for isolation of candidate
905 vaccine viruses in cells and an agreement with IFPMA for isolation of candidate vaccine viruses in eggs.
906 SGS reports honoraria from CSL Seqirus, Moderna, Pfizer, and Evo Health. The Icahn School of
907 Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines, SARS-CoV-2
908 serological assays, and SARS-CoV-2 vaccines which list FK as co-inventor. Mount Sinai has spun out
909 companies, Kantaro and Castlevax, to market the SARS-CoV-2 related technologies. FK has consulted
910 for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures,
911 GSK and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-

912 CoV-2 and with Dynavax on universal influenza virus vaccines. All other authors declare no competing
913 interests.

914

915 **Supplementary Methods**

916 **Influenza virological surveillance data**

917 Data on weekly influenza type and subtype circulation were obtained from the US CDC's World Health
918 Organization (WHO) Collaborating Center for Surveillance, Epidemiology and Control of Influenza [121].
919 Approximately 100 public health laboratories and 300 clinical laboratories located throughout the United
920 States report influenza test results to the US CDC, through either the US WHO Collaborating
921 Laboratories Systems or the National Respiratory and Enteric Virus Surveillance System (NREVSS).
922 Clinical laboratories test respiratory specimens for diagnostic purposes whereas public health laboratories
923 primarily test specimens to characterize influenza virus type, subtype, and lineage circulation. Public
924 health laboratories often receive samples that have already tested positive for influenza at a clinical
925 laboratory.

926 We estimated the weekly number of respiratory samples testing positive for influenza A(H1N1), A(H3N2),
927 or B at the HHS region level. Beginning in the 2015/2016 season, reports from public health and clinical
928 laboratories are presented separately in the CDC's weekly influenza updates. From 2015 week 40
929 onwards, we used clinical laboratory data to estimate the proportion of respiratory samples testing
930 positive for any influenza type/subtype and the proportion of samples testing positive for influenza A or B.
931 We used public health laboratory data to estimate the proportion of influenza A isolates typed as A(H3N2)
932 or A(H1N1)pdm09 in each week. Untyped influenza A-positive isolates were assigned to either A(H3N2)
933 or A(H1N1) according to their proportions among typed isolates. We combined seasonal and pandemic
934 A(H1N1) as seasonal A(H1N1) influenza and the Victoria and Yamagata lineages of influenza B as
935 influenza B. We defined influenza A subtype dominance in each season based on the proportion of
936 influenza A positive samples typed as A(H1N1) or A(H3N2).

937 **A(H3N2) epidemiological model**

938 Prior to R_t estimation, we computed daily case counts by disaggregating weekly A(H3N2) incidence rates
939 to daily rates (tempdisagg package) [183] and rounding the resultant values to integers. Observed cases
940 were modelled as a function of latent infections in the population, assuming a negative binomial
941 distribution. We assumed an infection ascertainment rate of 0.45 [184], a lognormal-distributed infection-
942 to-symptom-onset time period with mean 1.4 days and standard deviation 1.5 days [185], and a
943 lognormal-distributed onset-to-case-observation time period with mean 2 days and standard deviation 1.5
944 days [186]. Thus, the time distribution for infection-to-case-observation was

$$945 \quad \pi \sim \text{lognormal}(1.4, 1.5) + \text{lognormal}(2, 1.5)$$

946 Instead of using the renewal equation to propagate infections, we treated infections as latent parameters
947 in the model, because the additional variance around infections leads to a posterior distribution that is
948 easier to sample [125]. For the generation time, we assumed a discretized Weibull distribution with mean
949 3.6 days and standard deviation 1.6 days [187]. To control for temporal autocorrelation, we modelled R_t
950 as a daily random walk. We assigned the intercept a normal prior with mean $\log 2$ and variance 0.2, which
951 gives the initial reproduction number R_0 a prior mean of approximately 2.

952 Epidemic trajectories for each region and season were fit independently using Stan's Hamiltonian Monte
953 Carlo sampler [188]. For each model, we ran 4 chains, each for 10,000 iterations (including a burn-in
954 period of 2,000 iterations that was discarded), producing a total posterior sample size of 32,000. We
955 verified convergence by confirming that all parameters had sufficiently low \hat{R} values (all $\hat{R} < 1.1$)
956 and sufficiently large effective sample sizes (>15% of the total sample size).

957 Wavelet analysis

958 We applied a wavelet approach to quantify the relative timing of influenza A(H3N2), A(H1N1), and B
959 epidemics in each HHS region. Incidence time series were square root transformed and normalized and
960 then padded with zeros to reduce edge effects. Wavelet coherence was used to determine the degree of
961 synchrony between A(H3N2) versus A(H1N1) incidence and A(H3N2) versus B incidence within each
962 region at multi-year time scales. Statistical significance was assessed using 10,000 Monte Carlo
963 simulations. Coherence measures time- and frequency-specific associations between two wavelet
964 transforms, with high coherence indicating that two non-stationary signals (time series) are associated at
965 a particular time and frequency [82].

966 Following methodology developed for influenza and other viruses [19,82,189-191], we used continuous
967 wavelet transformations (Morlet) to calculate the phase of seasonal A(H3N2), A(H1N1), and B epidemics.
968 We reconstructed weekly time series of phase angles using wavelet reconstruction [19,192] and extracted
969 the major one-year seasonal component (period 0.8 to 1.2 years) of the Morlet decomposition of
970 A(H3N2), A(H1N1), and B time series. To estimate the relative timing of A(H3N2) and A(H1N1) incidence
971 or A(H3N2) and B incidence in each region, phase angle differences were calculated as phase in
972 A(H3N2) minus phase in A(H1N1) (or B), with a positive value indicating that A(H1N1) (or B) lags
973 A(H3N2).

974 References

- 975
- 976 1. Gerdil, C. (2003) The annual production cycle for influenza vaccine. *Vaccine* 21, 1776-1779.
977 10.1016/s0264-410x(03)00071-9
- 978 2. He, D. *et al.* (2015) Global Spatio-temporal Patterns of Influenza in the Post-pandemic Era. *Sci*
979 *Rep* 5, 11013. 10.1038/srep11013
- 980 3. Wraith, S. *et al.* (2022) Homotypic protection against influenza in a pediatric cohort in Managua,
981 Nicaragua. *Nat Commun* 13, 1190. 10.1038/s41467-022-28858-9
- 982 4. Hay, A.J. *et al.* (2001) The evolution of human influenza viruses. *Philos Trans R Soc Lond B Biol*
983 *Sci* 356, 1861-1870. 10.1098/rstb.2001.0999
- 984 5. Ferguson, N.M. *et al.* (2005) Strategies for containing an emerging influenza pandemic in
985 Southeast Asia. *Nature* 437, 209-214. 10.1038/nature04017
- 986 6. Bedford, T. *et al.* (2014) Integrating influenza antigenic dynamics with molecular evolution. *Elife* 3,
987 e01914. 10.7554/eLife.01914
- 988 7. Bedford, T. *et al.* (2015) Global circulation patterns of seasonal influenza viruses vary with
989 antigenic drift. *Nature* 523, 217-220. 10.1038/nature14460
- 990 8. Simonsen, L. (1999) The global impact of influenza on morbidity and mortality. *Vaccine* 17, S3-
991 S10. 10.1016/S0264-410X(99)00099-7
- 992 9. Viboud, C. *et al.* (2004) Influenza epidemics in the United States, France, and Australia, 1972-
993 1997. *Emerg Infect Dis* 10, 32-39. 10.3201/eid1001.020705
- 994 10. Chattopadhyay, I. *et al.* (2018) Conjunction of factors triggering waves of seasonal influenza. *Elife*
995 7. 10.7554/eLife.30756
- 996 11. Kramer, S.C. and Shaman, J. (2019) Development and validation of influenza forecasting for 64
997 temperate and tropical countries. *PLoS Comput Biol* 15, e1006742. 10.1371/journal.pcbi.1006742
- 998 12. Lee, E.C. *et al.* (2018) Deploying digital health data to optimize influenza surveillance at national
999 and local scales. *PLoS Comput Biol* 14, e1006020. 10.1371/journal.pcbi.1006020
- 1000 13. Shaman, J. *et al.* (2010) Absolute humidity and the seasonal onset of influenza in the continental
1001 United States. *PLoS Biol* 8, e1000316. 10.1371/journal.pbio.1000316
- 1002 14. Shaman, J. and Kohn, M. (2009) Absolute humidity modulates influenza survival, transmission,
1003 and seasonality. *Proc Natl Acad Sci U S A* 106, 3243-3248. 10.1073/pnas.0806852106
- 1004 15. Bedford, T. *et al.* (2010) Global migration dynamics underlie evolution and persistence of human
1005 influenza A (H3N2). *PLoS Pathog* 6, e1000918. 10.1371/journal.ppat.1000918
- 1006 16. Charu, V. *et al.* (2017) Human mobility and the spatial transmission of influenza in the United
1007 States. *PLoS Comput Biol* 13, e1005382. 10.1371/journal.pcbi.1005382

- 1008 17. Geoghegan, J.L. *et al.* (2018) Continental synchronicity of human influenza virus epidemics
1009 despite climatic variation. *PLoS Pathog* 14, e1006780. 10.1371/journal.ppat.1006780
- 1010 18. Pei, S. *et al.* (2018) Forecasting the spatial transmission of influenza in the United States. *Proc*
1011 *Natl Acad Sci U S A* 115, 2752-2757. 10.1073/pnas.1708856115
- 1012 19. Viboud, C. *et al.* (2006) Synchrony, waves, and spatial hierarchies in the spread of influenza.
1013 *Science* 312, 447-451. 10.1126/science.1125237
- 1014 20. Nelson, M.I. and Holmes, E.C. (2007) The evolution of epidemic influenza. *Nat Rev Genet* 8, 196-
1015 205. 10.1038/nrg2053
- 1016 21. Wiley, D.C. *et al.* (1981) Structural identification of the antibody-binding sites of Hong Kong
1017 influenza haemagglutinin and their involvement in antigenic variation. *Nature* 289, 373-378.
1018 10.1038/289373a0
- 1019 22. Fiore, A.E. *et al.* (2009) Prevention and control of seasonal influenza with vaccines:
1020 recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. *MMWR*
1021 *Recomm Rep* 58, 1-52
- 1022 23. Boni, M.F. *et al.* (2004) Influenza drift and epidemic size: the race between generating and
1023 escaping immunity. *Theor Popul Biol* 65, 179-191. 10.1016/j.tpb.2003.10.002
- 1024 24. Greene, S.K. *et al.* (2006) Patterns of influenza-associated mortality among US elderly by
1025 geographic region and virus subtype, 1968-1998. *Am J Epidemiol* 163, 316-326.
1026 10.1093/aje/kwj040
- 1027 25. Koelle, K. *et al.* (2009) Understanding the dynamics of rapidly evolving pathogens through
1028 modeling the tempo of antigenic change: influenza as a case study. *Epidemics* 1, 129-137.
1029 10.1016/j.epidem.2009.05.003
- 1030 26. Koelle, K. *et al.* (2006) Epochal evolution shapes the phylodynamics of interpandemic influenza A
1031 (H3N2) in humans. *Science* 314, 1898-1903. 10.1126/science.1132745
- 1032 27. Wolf, Y.I. *et al.* (2010) Projection of seasonal influenza severity from sequence and serological
1033 data. *PLoS Curr* 2, RRN1200. 10.1371/currents.RRN1200
- 1034 28. Wu, A. *et al.* (2010) Correlation of influenza virus excess mortality with antigenic variation:
1035 application to rapid estimation of influenza mortality burden. *PLoS Comput Biol* 6.
1036 10.1371/journal.pcbi.1000882
- 1037 29. Axelsen, J.B. *et al.* (2014) Multiannual forecasting of seasonal influenza dynamics reveals
1038 climatic and evolutionary drivers. *Proc Natl Acad Sci U S A* 111, 9538-9542.
1039 10.1073/pnas.1321656111
- 1040 30. Du, X. *et al.* (2017) Evolution-informed forecasting of seasonal influenza A (H3N2). *Sci Transl*
1041 *Med* 9. 10.1126/scitranslmed.aan5325
- 1042 31. Lam, E.K.S. *et al.* (2020) The impact of climate and antigenic evolution on seasonal influenza
1043 virus epidemics in Australia. *Nat Commun* 11, 2741. 10.1038/s41467-020-16545-6
- 1044 32. Smith, D.J. *et al.* (2004) Mapping the antigenic and genetic evolution of influenza virus. *Science*
1045 305, 371-376. 10.1126/science.1097211
- 1046 33. Bedford, T. *et al.* (2011) Strength and tempo of selection revealed in viral gene genealogies. *BMC*
1047 *Evol Biol* 11, 220. 10.1186/1471-2148-11-220
- 1048 34. Bhatt, S. *et al.* (2011) The genomic rate of molecular adaptation of the human influenza A virus.
1049 *Mol Biol Evol* 28, 2443-2451. 10.1093/molbev/msr044
- 1050 35. Huddleston, J. *et al.* (2020) Integrating genotypes and phenotypes improves long-term forecasts
1051 of seasonal influenza A/H3N2 evolution. *Elife* 9. 10.7554/eLife.60067
- 1052 36. Shih, A.C. *et al.* (2007) Simultaneous amino acid substitutions at antigenic sites drive influenza A
1053 hemagglutinin evolution. *Proc Natl Acad Sci U S A* 104, 6283-6288. 10.1073/pnas.0701396104
- 1054 37. Suzuki, Y. (2008) Positive selection operates continuously on hemagglutinin during evolution of
1055 H3N2 human influenza A virus. *Gene* 427, 111-116. 10.1016/j.gene.2008.09.012
- 1056 38. Chen, Y.Q. *et al.* (2018) Influenza Infection in Humans Induces Broadly Cross-Reactive and
1057 Protective Neuraminidase-Reactive Antibodies. *Cell* 173, 417-429 e410.
1058 10.1016/j.cell.2018.03.030

- 1059 39. Eichelberger, M.C. *et al.* (2018) Neuraminidase as an influenza vaccine antigen: a low hanging
1060 fruit, ready for picking to improve vaccine effectiveness. *Curr Opin Immunol* 53, 38-44.
1061 10.1016/j.coi.2018.03.025
- 1062 40. Wohlbold, T.J. *et al.* (2015) Vaccination with adjuvanted recombinant neuraminidase induces
1063 broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in
1064 mice. *mBio* 6, e02556. 10.1128/mBio.02556-14
- 1065 41. Brett, I.C. and Johansson, B.E. (2005) Immunization against influenza A virus: comparison of
1066 conventional inactivated, live-attenuated and recombinant baculovirus produced purified
1067 hemagglutinin and neuraminidase vaccines in a murine model system. *Virology* 339, 273-280.
1068 10.1016/j.virol.2005.06.006
- 1069 42. Couch, R.B. *et al.* (1974) Induction of partial immunity to influenza by a neuraminidase-specific
1070 vaccine. *J Infect Dis* 129, 411-420. 10.1093/infdis/129.4.411
- 1071 43. Johansson, B.E. *et al.* (1993) Infection-permissive immunization with influenza virus
1072 neuraminidase prevents weight loss in infected mice. *Vaccine* 11, 1037-1039. 10.1016/0264-
1073 410x(93)90130-p
- 1074 44. Kilbourne, E.D. (1976) Comparative efficacy of neuraminidase-specific and conventional
1075 influenza virus vaccines in induction of antibody to neuraminidase in humans. *J Infect Dis* 134,
1076 384-394. 10.1093/infdis/134.4.384
- 1077 45. Murphy, B.R. *et al.* (1972) Association of serum anti-neuraminidase antibody with resistance to
1078 influenza in man. *N Engl J Med* 286, 1329-1332. 10.1056/NEJM197206222862502
- 1079 46. Schulman, J.L. *et al.* (1968) Protective effects of specific immunity to viral neuraminidase on
1080 influenza virus infection of mice. *J Virol* 2, 778-786. 10.1128/JVI.2.8.778-786.1968
- 1081 47. Couch, R.B. *et al.* (2013) Antibody correlates and predictors of immunity to naturally occurring
1082 influenza in humans and the importance of antibody to the neuraminidase. *J Infect Dis* 207, 974-
1083 981. 10.1093/infdis/jis935
- 1084 48. Memoli, M.J. *et al.* (2016) Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as
1085 Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model. *mBio* 7,
1086 e00417-00416. 10.1128/mBio.00417-16
- 1087 49. Monto, A.S. *et al.* (2015) Antibody to Influenza Virus Neuraminidase: An Independent Correlate of
1088 Protection. *J Infect Dis* 212, 1191-1199. 10.1093/infdis/jiv195
- 1089 50. Grebe, K.M. *et al.* (2008) Heterosubtypic immunity to influenza A virus: where do we stand?
1090 *Microbes Infect* 10, 1024-1029. 10.1016/j.micinf.2008.07.002
- 1091 51. Ulmer, J.B. *et al.* (1998) Protective CD4+ and CD8+ T cells against influenza virus induced by
1092 vaccination with nucleoprotein DNA. *J Virol* 72, 5648-5653. 10.1128/JVI.72.7.5648-5653.1998
- 1093 52. Sridhar, S. *et al.* (2013) Cellular immune correlates of protection against symptomatic pandemic
1094 influenza. *Nat Med* 19, 1305-1312. 10.1038/nm.3350
- 1095 53. Epstein, S.L. (2006) Prior H1N1 influenza infection and susceptibility of Cleveland Family Study
1096 participants during the H2N2 pandemic of 1957: an experiment of nature. *J Infect Dis* 193, 49-53.
1097 10.1086/498980
- 1098 54. Sonoguchi, T. *et al.* (1985) Cross-subtype protection in humans during sequential, overlapping,
1099 and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. *J Infect Dis* 151, 81-
1100 88. 10.1093/infdis/151.1.81
- 1101 55. Ferguson, N.M. *et al.* (2003) Ecological and immunological determinants of influenza evolution.
1102 *Nature* 422, 428-433. 10.1038/nature01509
- 1103 56. Cowling, B.J. *et al.* (2014) Incidence of influenza virus infections in children in Hong Kong in a 3-
1104 year randomized placebo-controlled vaccine study, 2009-2012. *Clin Infect Dis* 59, 517-524.
1105 10.1093/cid/ciu356
- 1106 57. Goldstein, E. *et al.* (2011) Predicting the epidemic sizes of influenza A/H1N1, A/H3N2, and B: a
1107 statistical method. *PLoS Med* 8, e1001051. 10.1371/journal.pmed.1001051
- 1108 58. Steinhoff, M.C. *et al.* (1993) Effect of heterosubtypic immunity on infection with attenuated
1109 influenza A virus vaccines in young children. *J Clin Microbiol* 31, 836-838. 10.1128/jcm.31.4.836-
1110 838.1993

- 1111 59. Gatti, L. *et al.* (2022) Cross-reactive immunity potentially drives global oscillation and opposed
1112 alternation patterns of seasonal influenza A viruses. *Sci Rep* 12, 8883. 10.1038/s41598-022-
1113 08233-w
- 1114 60. Shu, Y. and McCauley, J. (2017) GISAID: Global initiative on sharing all influenza data - from
1115 vision to reality. *Euro Surveill* 22. 10.2807/1560-7917.ES.2017.22.13.30494
- 1116 61. Luksza, M. and Lassig, M. (2014) A predictive fitness model for influenza. *Nature* 507, 57-61.
1117 10.1038/nature13087
- 1118 62. Neher, R.A. *et al.* (2014) Predicting evolution from the shape of genealogical trees. *Elife* 3.
1119 10.7554/eLife.03568
- 1120 63. Neher, R.A. *et al.* (2016) Prediction, dynamics, and visualization of antigenic phenotypes of
1121 seasonal influenza viruses. *Proc Natl Acad Sci U S A* 113, E1701-1709.
1122 10.1073/pnas.1525578113
- 1123 64. Bush, R.M. *et al.* (1999) Predicting the evolution of human influenza A. *Science* 286, 1921-1925.
1124 10.1126/science.286.5446.1921
- 1125 65. Webster, R.G. and Laver, W.G. (1980) Determination of the number of nonoverlapping antigenic
1126 areas on Hong Kong (H3N2) influenza virus hemagglutinin with monoclonal antibodies and the
1127 selection of variants with potential epidemiological significance. *Virology* 104, 139-148.
1128 10.1016/0042-6822(80)90372-4
- 1129 66. Wilson, I.A. and Cox, N.J. (1990) Structural basis of immune recognition of influenza virus
1130 hemagglutinin. *Annu Rev Immunol* 8, 737-771. 10.1146/annurev.iy.08.040190.003513
- 1131 67. Wolf, Y.I. *et al.* (2006) Long intervals of stasis punctuated by bursts of positive selection in the
1132 seasonal evolution of influenza A virus. *Biol Direct* 1, 34. 10.1186/1745-6150-1-34
- 1133 68. Koel, B.F. *et al.* (2013) Substitutions near the receptor binding site determine major antigenic
1134 change during influenza virus evolution. *Science* 342, 976-979. 10.1126/science.1244730
- 1135 69. Krammer, F. (2023) Unpublished.
- 1136 70. Kirkpatrick, E. *et al.* (2018) The influenza virus hemagglutinin head evolves faster than the stalk
1137 domain. *Sci Rep* 8, 10432. 10.1038/s41598-018-28706-1
- 1138 71. Krammer, F. (2019) The human antibody response to influenza A virus infection and vaccination.
1139 *Nat Rev Immunol* 19, 383-397. 10.1038/s41577-019-0143-6
- 1140 72. Margine, I. *et al.* (2013) H3N2 influenza virus infection induces broadly reactive hemagglutinin
1141 stalk antibodies in humans and mice. *J Virol* 87, 4728-4737. 10.1128/JVI.03509-12
- 1142 73. Nachbagauer, R. *et al.* (2016) Age Dependence and Isotype Specificity of Influenza Virus
1143 Hemagglutinin Stalk-Reactive Antibodies in Humans. *mBio* 7, e01996-01915.
1144 10.1128/mBio.01996-15
- 1145 74. Sandbulte, M.R. *et al.* (2011) Discordant antigenic drift of neuraminidase and hemagglutinin in
1146 H1N1 and H3N2 influenza viruses. *Proc Natl Acad Sci U S A* 108, 20748-20753.
1147 10.1073/pnas.1113801108
- 1148 75. Kilbourne, E.D. *et al.* (1990) Independent and disparate evolution in nature of influenza A virus
1149 hemagglutinin and neuraminidase glycoproteins. *Proc Natl Acad Sci U S A* 87, 786-790.
1150 10.1073/pnas.87.2.786
- 1151 76. Schulman, J.L. and Kilbourne, E.D. (1969) Independent variation in nature of hemagglutinin and
1152 neuraminidase antigens of influenza virus: distinctiveness of hemagglutinin antigen of Hong
1153 Kong-68 virus. *Proc Natl Acad Sci U S A* 63, 326-333. 10.1073/pnas.63.2.326
- 1154 77. Goldstein, E. *et al.* (2012) Improving the estimation of influenza-related mortality over a seasonal
1155 baseline. *Epidemiology* 23, 829-838. 10.1097/EDE.0b013e31826c2dda
- 1156 78. Gostic, K.M. *et al.* (2019) Childhood immune imprinting to influenza A shapes birth year-specific
1157 risk during seasonal H1N1 and H3N2 epidemics. *PLoS Pathog* 15, e1008109.
1158 10.1371/journal.ppat.1008109
- 1159 79. Webster, R.G. *et al.* (1992) Evolution and ecology of influenza A viruses. *Microbiological Reviews*
1160 56, 152-179. doi:10.1128/mr.56.1.152-179.1992
- 1161 80. Garten, R.J. *et al.* (2009) Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1)
1162 Influenza Viruses Circulating in Humans. *Science* 325, 197-201. doi:10.1126/science.1176225

- 1163 81. Smith, G.J. *et al.* (2009) Origins and evolutionary genomics of the 2009 swine-origin H1N1
1164 influenza A epidemic. *Nature* 459, 1122-1125. 10.1038/nature08182
- 1165 82. Johansson, M.A. *et al.* (2009) Multiyear climate variability and dengue--El Nino southern
1166 oscillation, weather, and dengue incidence in Puerto Rico, Mexico, and Thailand: a longitudinal
1167 data analysis. *PLoS Med* 6, e1000168. 10.1371/journal.pmed.1000168
- 1168 83. Bedford, T. *et al.* (2012) Canalization of the evolutionary trajectory of the human influenza virus.
1169 *BMC Biol* 10, 38. 10.1186/1741-7007-10-38
- 1170 84. Petrova, V.N. and Russell, C.A. (2018) The evolution of seasonal influenza viruses. *Nat Rev*
1171 *Microbiol* 16, 47-60. 10.1038/nrmicro.2017.118
- 1172 85. Koelle, K. and Rasmussen, D.A. (2015) The effects of a deleterious mutation load on patterns of
1173 influenza A/H3N2's antigenic evolution in humans. *Elife* 4, e07361. 10.7554/eLife.07361
- 1174 86. Kryazhimskiy, S. *et al.* (2011) Prevalence of epistasis in the evolution of influenza A surface
1175 proteins. *PLoS Genet* 7, e1001301. 10.1371/journal.pgen.1001301
- 1176 87. Gong, L.I. *et al.* (2013) Stability-mediated epistasis constrains the evolution of an influenza
1177 protein. *Elife* 2, e00631. 10.7554/eLife.00631
- 1178 88. Myers, J.L. *et al.* (2013) Compensatory hemagglutinin mutations alter antigenic properties of
1179 influenza viruses. *J Virol* 87, 11168-11172. 10.1128/JVI.01414-13
- 1180 89. Webster, R.G. *et al.* (1982) Molecular mechanisms of variation in influenza viruses. *Nature* 296,
1181 115-121. 10.1038/296115a0
- 1182 90. Altman, M.O. *et al.* (2015) Lamprey VLRB response to influenza virus supports universal rules of
1183 immunogenicity and antigenicity. *Elife* 4. 10.7554/eLife.07467
- 1184 91. Ndifon, W. *et al.* (2009) On the use of hemagglutination-inhibition for influenza surveillance:
1185 surveillance data are predictive of influenza vaccine effectiveness. *Vaccine* 27, 2447-2452.
1186 10.1016/j.vaccine.2009.02.047
- 1187 92. Hensley, S.E. (2014) Challenges of selecting seasonal influenza vaccine strains for humans with
1188 diverse pre-exposure histories. *Curr Opin Virol* 8, 85-89. 10.1016/j.coviro.2014.07.007
- 1189 93. Lee, J.M. *et al.* (2019) Mapping person-to-person variation in viral mutations that escape
1190 polyclonal serum targeting influenza hemagglutinin. *Elife* 8. 10.7554/eLife.49324
- 1191 94. Li, Y. *et al.* (2013) Immune history shapes specificity of pandemic H1N1 influenza antibody
1192 responses. *J Exp Med* 210, 1493-1500. 10.1084/jem.20130212
- 1193 95. Miller, M.S. *et al.* (2013) Neutralizing antibodies against previously encountered influenza virus
1194 strains increase over time: a longitudinal analysis. *Sci Transl Med* 5, 198ra107.
1195 10.1126/scitranslmed.3006637
- 1196 96. Henry, C. *et al.* (2019) Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in
1197 Elderly Individuals. *Cell Host Microbe* 25, 357-366 e356. 10.1016/j.chom.2019.01.002
- 1198 97. Ranjeva, S. *et al.* (2019) Age-specific differences in the dynamics of protective immunity to
1199 influenza. *Nat Commun* 10, 1660. 10.1038/s41467-019-09652-6
- 1200 98. Cobey, S. and Hensley, S.E. (2017) Immune history and influenza virus susceptibility. *Curr Opin*
1201 *Virol* 22, 105-111. 10.1016/j.coviro.2016.12.004
- 1202 99. Zhang, A. *et al.* (2019) Original Antigenic Sin: How First Exposure Shapes Lifelong Anti-Influenza
1203 Virus Immune Responses. *J Immunol* 202, 335-340. 10.4049/jimmunol.1801149
- 1204 100. Zost, S.J. *et al.* (2017) Contemporary H3N2 influenza viruses have a glycosylation site that alters
1205 binding of antibodies elicited by egg-adapted vaccine strains. *Proc Natl Acad Sci U S A* 114,
1206 12578-12583. 10.1073/pnas.1712377114
- 1207 101. Xie, H. *et al.* (2015) H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and
1208 Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps. *Sci Rep*
1209 5, 15279. 10.1038/srep15279
- 1210 102. Cowling, B.J. *et al.* (2010) Protective efficacy of seasonal influenza vaccination against seasonal
1211 and pandemic influenza virus infection during 2009 in Hong Kong. *Clin Infect Dis* 51, 1370-1379.
1212 10.1086/657311
- 1213 103. Fox, S.J. *et al.* (2017) Seasonality in risk of pandemic influenza emergence. *PLoS Comput Biol*
1214 13, e1005749. 10.1371/journal.pcbi.1005749

- 1215 104. Laurie, K.L. *et al.* (2015) Interval Between Infections and Viral Hierarchy Are Determinants of
1216 Viral Interference Following Influenza Virus Infection in a Ferret Model. *J Infect Dis* 212, 1701-
1217 1710. 10.1093/infdis/jiv260
- 1218 105. Garten, R.J. *et al.* (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1)
1219 influenza viruses circulating in humans. *Science* 325, 197-201. 10.1126/science.1176225
- 1220 106. Terajima, M. *et al.* (2013) Cross-reactive human B cell and T cell epitopes between influenza A
1221 and B viruses. *Virology* 10, 244. 10.1186/1743-422x-10-244
- 1222 107. Yang, W. *et al.* (2020) Dynamic interactions of influenza viruses in Hong Kong during 1998-2018.
1223 *PLoS Comput Biol* 16, e1007989. 10.1371/journal.pcbi.1007989
- 1224 108. Cowling, B.J. *et al.* (2020) Impact assessment of non-pharmaceutical interventions against
1225 coronavirus disease 2019 and influenza in Hong Kong: an observational study. *Lancet Public*
1226 *Health* 5, e279-e288. 10.1016/S2468-2667(20)30090-6
- 1227 109. Huang, Q.S. *et al.* (2021) Impact of the COVID-19 nonpharmaceutical interventions on influenza
1228 and other respiratory viral infections in New Zealand. *Nat Commun* 12, 1001. 10.1038/s41467-
1229 021-21157-9
- 1230 110. Olsen, S.J. *et al.* (2020) Decreased influenza activity during the COVID-19 pandemic-United
1231 States, Australia, Chile, and South Africa, 2020. *Am J Transplant* 20, 3681-3685.
1232 10.1111/ajt.16381
- 1233 111. Olsen, S.J. *et al.* (2021) Changes in Influenza and Other Respiratory Virus Activity During the
1234 COVID-19 Pandemic - United States, 2020-2021. *MMWR Morb Mortal Wkly Rep* 70, 1013-1019.
1235 10.15585/mmwr.mm7029a1
- 1236 112. Qi, Y. *et al.* (2021) Quantifying the Impact of COVID-19 Nonpharmaceutical Interventions on
1237 Influenza Transmission in the United States. *J Infect Dis* 224, 1500-1508. 10.1093/infdis/jiab485
- 1238 113. Tempia, S. *et al.* (2021) Decline of influenza and respiratory syncytial virus detection in facility-
1239 based surveillance during the COVID-19 pandemic, South Africa, January to October 2020. *Euro*
1240 *Surveill* 26. 10.2807/1560-7917.ES.2021.26.29.2001600
- 1241 114. Ali, S.T. *et al.* (2022) Prediction of upcoming global infection burden of influenza seasons after
1242 relaxation of public health and social measures during the COVID-19 pandemic: a modelling
1243 study. *Lancet Glob Health* 10, e1612-e1622. 10.1016/S2214-109X(22)00358-8
- 1244 115. Baker, R.E. *et al.* (2020) The impact of COVID-19 nonpharmaceutical interventions on the future
1245 dynamics of endemic infections. *Proc Natl Acad Sci U S A* 117, 30547-30553.
1246 10.1073/pnas.2013182117
- 1247 116. Gaglani, M. *et al.* (2016) Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza
1248 A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. *J Infect Dis* 213,
1249 1546-1556. 10.1093/infdis/jiv577
- 1250 117. Gill, P.W. and Murphy, A.M. (1977) Naturally acquired immunity to influenza type A: a further
1251 prospective study. *Med J Aust* 2, 761-765. 10.5694/j.1326-5377.1977.tb99276.x
- 1252 118. Hope-Simpson, R.E. (1971) Hong Kong influenza variant. *Br Med J* 3, 531.
1253 10.1136/bmj.3.5773.531-b
- 1254 119. Krammer, F. *et al.* (2018) NAction! How Can Neuraminidase-Based Immunity Contribute to Better
1255 Influenza Virus Vaccines? *mBio* 9. 10.1128/mBio.02332-17
- 1256 120. Centers for Disease Control and Prevention (2023). FluView Interactive. Centers for Disease
1257 Control and Prevention
- 1258 121. World Health Organization (2023). FluNet.
- 1259 122. Pei, S. *et al.* (2021) Optimizing respiratory virus surveillance networks using uncertainty
1260 propagation. *Nat Commun* 12, 222. 10.1038/s41467-020-20399-3
- 1261 123. Dalziel, B.D. *et al.* (2018) Urbanization and humidity shape the intensity of influenza epidemics in
1262 U.S. cities. *Science* 362, 75-79. 10.1126/science.aat6030
- 1263 124. Cori, A. *et al.* (2013) A new framework and software to estimate time-varying reproduction
1264 numbers during epidemics. *Am J Epidemiol* 178, 1505-1512. 10.1093/aje/kwt133
- 1265 125. Scott, J.A. *et al.* (2021) Epidemia: An R package for semi-mechanistic bayesian modelling of
1266 infectious diseases using point processes. *arXiv preprint arXiv:2110.12461*,


- 1267 126. Carpenter, B. *et al.* (2017) Stan: A Probabilistic Programming Language. *Journal of Statistical Software* 76, 1 - 32. 10.18637/jss.v076.i01
- 1268
- 1269 127. Hansen, C.L. *et al.* (2022) Mortality Associated With Influenza and Respiratory Syncytial Virus in
- 1270 the US, 1999-2018. *JAMA Netw Open* 5, e220527. 10.1001/jamanetworkopen.2022.0527
- 1271 128. Simonsen, L. and Viboud, C. (2012) The art of modeling the mortality impact of winter-seasonal
- 1272 pathogens. *J Infect Dis* 206, 625-627. 10.1093/infdis/jis419
- 1273 129. Centers for Disease Control and Prevention (2019). Flu Vaccination Coverage, United States,
- 1274 2018–19 Influenza Season | FluVaxView | Seasonal Influenza (Flu) | CDC.
- 1275 130. Jang, S.H. and Kang, J. (2021) Factors Associated with Influenza Vaccination Uptake among
- 1276 U.S. Adults: Focus on Nativity and Race/Ethnicity. *Int J Environ Res Public Health* 18.
- 1277 10.3390/ijerph18105349
- 1278 131. Lu, P.J. *et al.* (2019) Seasonal Influenza Vaccination Coverage Trends Among Adult Populations,
- 1279 U.S., 2010-2016. *Am J Prev Med* 57, 458-469. 10.1016/j.amepre.2019.04.007
- 1280 132. Lu, P.J. *et al.* (2013) Seasonal influenza vaccination coverage among adult populations in the
- 1281 United States, 2005-2011. *Am J Epidemiol* 178, 1478-1487. 10.1093/aje/kwt158
- 1282 133. National Center for Health Statistics (2008). TABLE: Self-reported influenza vaccination coverage
- 1283 trends 1989-2008 among adults by age group, risk group, race/ethnicity, health-care worker
- 1284 status, and pregnancy status. National Health Interview Survey (NHIS)
- 1285 134. Ward, B. *et al.* (2014). Early Release of Selected Estimates Based on Data From the 2014
- 1286 National Health Interview Survey. In Statistics, N.C.f.H., ed.
- 1287 135. Ward, B. *et al.* (2016). Early Release of Selected Estimates Based on Data From the 2015
- 1288 National Health Interview Survey (05/2016). In Statistics, N.C.f.H., ed.
- 1289 136. Belongia, E.A. *et al.* (2011) Influenza vaccine effectiveness in Wisconsin during the 2007-08
- 1290 season: comparison of interim and final results. *Vaccine* 29, 6558-6563.
- 1291 10.1016/j.vaccine.2011.07.002
- 1292 137. Bridges, C.B. *et al.* (2000) Effectiveness and cost-benefit of influenza vaccination of healthy
- 1293 working adults: A randomized controlled trial. *JAMA* 284, 1655-1663. 10.1001/jama.284.13.1655
- 1294 138. Castilla, J. *et al.* (2016) Effectiveness of subunit influenza vaccination in the 2014-2015 season
- 1295 and residual effect of split vaccination in previous seasons. *Vaccine* 34, 1350-1357.
- 1296 10.1016/j.vaccine.2016.01.054
- 1297 139. Flannery, B. *et al.* (2019) Influenza Vaccine Effectiveness in the United States During the 2016-
- 1298 2017 Season. *Clin Infect Dis* 68, 1798-1806. 10.1093/cid/ciy775
- 1299 140. Flannery, B. *et al.* (2020) Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine
- 1300 Effectiveness in the United States During the 2018-2019 Season. *J Infect Dis* 221, 8-15.
- 1301 10.1093/infdis/jiz543
- 1302 141. Flannery, B. *et al.* (2016) Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and
- 1303 Vaccine Effectiveness by Genetic Group, 2014-2015. *J Infect Dis* 214, 1010-1019.
- 1304 10.1093/infdis/jiw181
- 1305 142. Jackson, M.L. *et al.* (2017) Influenza Vaccine Effectiveness in the United States during the 2015-
- 1306 2016 Season. *N Engl J Med* 377, 534-543. 10.1056/NEJMoa1700153
- 1307 143. Janjua, N.Z. *et al.* (2012) Estimates of influenza vaccine effectiveness for 2007-2008 from
- 1308 Canada's sentinel surveillance system: cross-protection against major and minor variants. *J Infect*
- 1309 *Dis* 205, 1858-1868. 10.1093/infdis/jis283
- 1310 144. Kawai, N. *et al.* (2003) A prospective, Internet-based study of the effectiveness and safety of
- 1311 influenza vaccination in the 2001-2002 influenza season. *Vaccine* 21, 4507-4513. 10.1016/s0264-
- 1312 410x(03)00508-5
- 1313 145. Kissling, E. *et al.* (2013) Low and decreasing vaccine effectiveness against influenza A(H3) in
- 1314 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-
- 1315 control study. *Euro Surveill* 18. 10.2807/ese.18.05.20390-en
- 1316 146. Lester, R.T. *et al.* (2003) Use of, effectiveness of, and attitudes regarding influenza vaccine
- 1317 among house staff. *Infect Control Hosp Epidemiol* 24, 839-844. 10.1086/502146
- 1318 147. McLean, H.Q. *et al.* (2014) Impact of repeated vaccination on vaccine effectiveness against
- 1319 influenza A(H3N2) and B during 8 seasons. *Clin Infect Dis* 59, 1375-1385. 10.1093/cid/ciu680

- 1320 148. Ohmit, S.E. *et al.* (2014) Influenza vaccine effectiveness in the 2011-2012 season: protection
1321 against each circulating virus and the effect of prior vaccination on estimates. *Clin Infect Dis* 58,
1322 319-327. 10.1093/cid/cit736
- 1323 149. Pebody, R. *et al.* (2017) End-of-season influenza vaccine effectiveness in adults and children,
1324 United Kingdom, 2016/17. *Euro Surveill* 22. 10.2807/1560-7917.ES.2017.22.44.17-00306
- 1325 150. Centers for Disease Control and Prevention (2004) Assessment of the effectiveness of the 2003-
1326 04 influenza vaccine among children and adults--Colorado, 2003. *MMWR Morb Mortal Wkly Rep*
1327 53, 707-710
- 1328 151. Rolfes, M.A. *et al.* (2019) Effects of Influenza Vaccination in the United States During the 2017-
1329 2018 Influenza Season. *Clin Infect Dis* 69, 1845-1853. 10.1093/cid/ciz075
- 1330 152. Simpson, C.R. *et al.* (2015) Trivalent inactivated seasonal influenza vaccine effectiveness for the
1331 prevention of laboratory-confirmed influenza in a Scottish population 2000 to 2009. *Euro Surveill*
1332 20. 10.2807/1560-7917.es2015.20.8.21043
- 1333 153. Skowronski, D. *et al.* (2005) Effectiveness of vaccine against medical consultation due to
1334 laboratory-confirmed influenza: results from a sentinel physician pilot project in British Columbia,
1335 2004-2005. *Can Commun Dis Rep* 31, 181-191
- 1336 154. Skowronski, D.M. *et al.* (2007) Estimating vaccine effectiveness against laboratory-confirmed
1337 influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B
1338 vaccine mismatch in Canada. *Vaccine* 25, 2842-2851. 10.1016/j.vaccine.2006.10.002
- 1339 155. Skowronski, D.M. *et al.* (2009) Component-specific effectiveness of trivalent influenza vaccine as
1340 monitored through a sentinel surveillance network in Canada, 2006-2007. *J Infect Dis* 199, 168-
1341 179. 10.1086/595862
- 1342 156. Skowronski, D.M. *et al.* (2010) Association between the 2008-09 seasonal influenza vaccine and
1343 pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada.
1344 *PLoS Med* 7, e1000258. 10.1371/journal.pmed.1000258
- 1345 157. Skowronski, D.M. *et al.* (2012) A sentinel platform to evaluate influenza vaccine effectiveness and
1346 new variant circulation, Canada 2010-2011 season. *Clin Infect Dis* 55, 332-342.
1347 10.1093/cid/cis431
- 1348 158. Skowronski, D.M. *et al.* (2014) Low 2012-13 influenza vaccine effectiveness associated with
1349 mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. *PLoS*
1350 *One* 9, e92153. 10.1371/journal.pone.0092153
- 1351 159. Skowronski, D.M. *et al.* (2014) Influenza A/subtype and B/lineage effectiveness estimates for the
1352 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
1353 *J Infect Dis* 210, 126-137. 10.1093/infdis/jiu048
- 1354 160. Skowronski, D.M. *et al.* (2017) Interim estimates of 2016/17 vaccine effectiveness against
1355 influenza A(H3N2), Canada, January 2017. *Euro Surveill* 22. 10.2807/1560-
1356 7917.ES.2017.22.6.30460
- 1357 161. Skowronski, D.M. *et al.* (2022) Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic
1358 Subcluster and Prior Vaccination History: 2016-2017 and 2017-2018 Epidemics in Canada. *J*
1359 *Infect Dis* 225, 1387-1398. 10.1093/infdis/jiaa138
- 1360 162. Skowronski, D.M. *et al.* (2016) A Perfect Storm: Impact of Genomic Variation and Serial
1361 Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season. *Clin Infect*
1362 *Dis* 63, 21-32. 10.1093/cid/ciw176
- 1363 163. Skowronski, D.M. *et al.* (2017) Serial Vaccination and the Antigenic Distance Hypothesis: Effects
1364 on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010-2011 to 2014-
1365 2015. *J Infect Dis* 215, 1059-1099. 10.1093/infdis/jix074
- 1366 164. Treanor, J.J. *et al.* (2012) Effectiveness of seasonal influenza vaccines in the United States
1367 during a season with circulation of all three vaccine strains. *Clin Infect Dis* 55, 951-959.
1368 10.1093/cid/cis574
- 1369 165. Valenciano, M. *et al.* (2018) Exploring the effect of previous inactivated influenza vaccination on
1370 seasonal influenza vaccine effectiveness against medically attended influenza: Results of the
1371 European I-MOVE multicentre test-negative case-control study, 2011/2012-2016/2017. *Influenza*
1372 *Other Respir Viruses* 12, 567-581. 10.1111/irv.12562


- 1373 166. van Doorn, E. *et al.* (2017) Influenza vaccine effectiveness estimates in the Dutch population from
1374 2003 to 2014: The test-negative design case-control study with different control groups. *Vaccine*
1375 35, 2831-2839. 10.1016/j.vaccine.2017.04.012
- 1376 167. Zimmerman, R.K. *et al.* (2016) 2014-2015 Influenza Vaccine Effectiveness in the United States
1377 by Vaccine Type. *Clin Infect Dis* 63, 1564-1573. 10.1093/cid/ciw635
- 1378 168. Benjamini, Y. and Hochberg, Y. (1995) Controlling the False Discovery Rate - a Practical and
1379 Powerful Approach to Multiple Testing. *J R Stat Soc B* 57, 289-300. DOI 10.1111/j.2517-
1380 6161.1995.tb02031.x
- 1381 169. Hadfield, J. *et al.* (2018) Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* 34,
1382 4121-4123. 10.1093/bioinformatics/bty407
- 1383 170. Katoh, K. *et al.* (2002) MAFFT: a novel method for rapid multiple sequence alignment based on
1384 fast Fourier transform. *Nucleic Acids Res* 30, 3059-3066. 10.1093/nar/gkf436
- 1385 171. Nguyen, L.T. *et al.* (2015) IQ-TREE: a fast and effective stochastic algorithm for estimating
1386 maximum-likelihood phylogenies. *Mol Biol Evol* 32, 268-274. 10.1093/molbev/msu300
- 1387 172. Sagulenko, P. *et al.* (2018) TreeTime: Maximum-likelihood phylodynamic analysis. *Virus Evol* 4,
1388 vex042. 10.1093/ve/vex042
- 1389 173. Huddleston, J. *et al.* (2021) Augur: a bioinformatics toolkit for phylogenetic analyses of human
1390 pathogens. *J Open Source Softw* 6. 10.21105/joss.02906
- 1391 174. Munoz, E.T. and Deem, M.W. (2005) Epitope analysis for influenza vaccine design. *Vaccine* 23,
1392 1144-1148. 10.1016/j.vaccine.2004.08.028
- 1393 175. Shannon, C.E. (1948) A mathematical theory of communication. *The Bell system technical journal*
1394 27, 379-423
- 1395 176. Hothorn, T. *et al.* (2006) Survival ensembles. *Biostatistics* 7, 355-373.
1396 10.1093/biostatistics/kxj011
- 1397 177. Strobl, C. *et al.* (2007) Bias in random forest variable importance measures: illustrations, sources
1398 and a solution. *BMC Bioinformatics* 8, 25. 10.1186/1471-2105-8-25
- 1399 178. Strobl, C. *et al.* (2008) Conditional variable importance for random forests. *BMC Bioinformatics* 9,
1400 307. 10.1186/1471-2105-9-307
- 1401 179. Kuhn, M. (2008) Building Predictive Models in R Using the caret Package. *Journal of Statistical*
1402 *Software* 28, 1 - 26. 10.18637/jss.v028.i05
- 1403 180. Altmann, A. *et al.* (2010) Permutation importance: a corrected feature importance measure.
1404 *Bioinformatics* 26, 1340-1347. 10.1093/bioinformatics/btq134
- 1405 181. Debeer, D. and Strobl, C. (2020) Conditional permutation importance revisited. *BMC*
1406 *Bioinformatics* 21, 307. 10.1186/s12859-020-03622-2
- 1407 182. Friedman, J. *et al.* (2010) Regularization Paths for Generalized Linear Models via Coordinate
1408 Descent. *J Stat Softw* 33, 1-22. 10.18637/jss.v033.i01
- 1409 183. Sax, C. and Steiner, P. (2013) Temporal Disaggregation of Time Series. *R J.* 5, 80
- 1410 184. Biggerstaff, M. *et al.* (2014) Influenza-like illness, the time to seek healthcare, and influenza
1411 antiviral receipt during the 2010-2011 influenza season-United States. *J Infect Dis* 210, 535-544.
1412 10.1093/infdis/jiu224
- 1413 185. Lessler, J. *et al.* (2009) Incubation periods of acute respiratory viral infections: a systematic
1414 review. *Lancet Infect Dis* 9, 291-300. 10.1016/s1473-3099(09)70069-6
- 1415 186. Russell, K.E. *et al.* (2018) Comparison of outpatient medically attended and community-level
1416 influenza-like illness-New York City, 2013-2015. *Influenza Other Respir Viruses* 12, 336-343.
1417 10.1111/irv.12540
- 1418 187. Cowling, B.J. *et al.* (2009) Estimation of the serial interval of influenza. *Epidemiology* 20, 344-347.
1419 10.1097/EDE.0b013e31819d1092
- 1420 188. Hoffman, M.D. and Gelman, A. (2014) The No-U-Turn sampler: adaptively setting path lengths in
1421 Hamiltonian Monte Carlo. *J. Mach. Learn. Res.* 15, 1593-1623
- 1422 189. Grenfell, B.T. *et al.* (2001) Travelling waves and spatial hierarchies in measles epidemics. *Nature*
1423 414, 716-723. 10.1038/414716a
- 1424 190. Liebhold, A. *et al.* (2004) Spatial Synchrony in Population Dynamics. *Annual Review of Ecology,*
1425 *Evolution, and Systematics* 35, 467-490. 10.1146/annurev.ecolsys.34.011802.132516

- 1426 191. Weinberger, D.M. *et al.* (2012) Influenza epidemics in Iceland over 9 decades: changes in timing
1427 and synchrony with the United States and Europe. *Am J Epidemiol* 176, 649-655.
1428 10.1093/aje/kws140
1429 192. Torrence, C. and Compo, G.P. (1998) A Practical Guide to Wavelet Analysis. *Bulletin of the*
1430 *American Meteorological Society* 79, 61-78. [https://doi.org/10.1175/1520-](https://doi.org/10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2)
1431 [0477\(1998\)079<0061:APGTWA>2.0.CO;2](https://doi.org/10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2)
1432


1433 **Figures**




1434 **Figure 1. Antigenic and genetic evolution of seasonal influenza A(H3N2) viruses, 1997 - 2019. A-B.**
 1435 Temporal phylogenies of hemagglutinin (H3) and neuraminidase (N2) gene segments. Tip color denotes
 1436 the Hamming distance from the root of the tree, based on the number of substitutions at epitope sites in
 1437 H3 (N = 129 sites) and N2 (N = 223 sites). “X” marks indicate the phylogenetic positions of US
 1438 recommended vaccine strains. **C-D.** Seasonal genetic and antigenic distances are the mean distance
 1439 between A(H3N2) viruses circulating in the current season t versus the prior season ($t - 1$), measured by
 1440 **C.** four sequence-based metrics (HA receptor binding site (RBS), HA stalk footprint, HA epitope, and NA
 1441 epitope) and **D.** hemagglutination inhibition (HI) titer measurements. **E.** The Shannon entropy of H3 and
 1442 N2 local branching index (LBI) values in each season. Vertical bars in **C**, **D**, and **E** and are 95%
 1443 confidence intervals of seasonal estimates from five bootstrapped phylogenies.
 1444



1445
1446 **Figure 2. Annual influenza A(H3N2) epidemics in the United States, 1997 - 2019. A.** Weekly
1447 incidence of influenza A(H3N2) (red), A(H1N1) (blue), and B (green) averaged across ten HHS regions
1448 (Region 1: Boston; Region 2: New York City; Region 3: Washington, DC; Region 4: Atlanta; Region 5:
1449 Chicago; Region 6: Dallas, Region 7: Kansas City; Region 8: Denver; Region 9: San Francisco; Region
1450 10: Seattle). Time series are 95% confidence intervals of regional incidence estimates. Incidences are the
1451 proportion of influenza-like illness (ILI) visits among all outpatient visits, multiplied by the proportion of
1452 respiratory samples testing positive for each influenza type/subtype. Vertical dashed lines indicate
1453 January 1 of each year. **B.** Intensity of weekly influenza A(H3N2) incidence in ten HHS regions. White
1454 tiles indicate weeks when influenza-like-illness data or virological data were not reported. Weekly
1455 time series for A(H1N1) and B are in Figure S5.




1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468



1469
 1470
 1471 **Figure 4. The proportion of influenza positive samples typed as A(H3N2) increases with antigenic**
 1472 **drift. A-B.** Seasonal A(H3N2) subtype dominance increases with H3 and N2 epitope distance. Seasonal
 1473 epitope distance is the mean epitope distance between viruses circulating in the current season t versus
 1474 the prior season ($t-1$) or two prior seasons ($t-2$). Distances were scaled to aid in direct comparison of
 1475 evolutionary indicators. Point color indicates the dominant influenza A virus (IAV) subtype based on CDC
 1476 influenza season summary reports (red: A(H3N2), blue: A(H1N1), purple: A(H1N1)pdm09, orange:
 1477 A(H3N2)/A(H1N1)pdm09 co-dominant), and vertical bands are 95% confidence intervals of regional
 1478 estimates. Seasonal mean A(H3N2) dominance was fit as a function of H3 or N2 epitope distance using
 1479 Beta GLMs with 1000 bootstrap resamples. **C-D.** Regional patterns of influenza type and subtype
 1480 incidence during two seasons when A(H3N2) was nationally dominant. **C.** Widespread A(H3N2)
 1481 dominance during 2003-2004 after the emergence of a novel antigenic cluster, FU02 (A/Fujian/411/2002-
 1482 like strains). **D.** Spatial heterogeneity in subtype circulation during 2007-2008, a season with low A(H3N2)
 1483 antigenic novelty relative to the prior season. Pie charts represent the proportion of influenza positive
 1484 samples typed as A(H3N2) (red), A(H1N1) (blue), or B (green) in each HHS region. Data for Region 10
 1485 (purple) were not available for seasons prior to 2009. The sizes of regional pie charts are proportional to
 the total number of influenza positive samples.

1486



1487

1488

1489

1490

1491

1492

1493


1494

1495


1496

1497

Figure 5. The effects of influenza A(H1N1) and B epidemic size on A(H3N2) epidemic burden. A. Influenza A(H1N1) epidemic size negatively correlates with A(H3N2) epidemic size, peak incidence, transmissibility (effective reproduction number, R_t), and epidemic intensity. **B.** Influenza B epidemic size does not significantly correlate with A(H3N2) epidemic metrics. Point color indicates the dominant influenza A virus (IAV) subtype based on CDC influenza season summary reports (red: A(H3N2), blue: A(H1N1), purple: A(H1N1)pdm09, orange: A(H3N2)/A(H1N1)pdm09 co-dominant), and vertical and horizontal bands are 95% confidence intervals of regional estimates. Seasonal mean A(H3N2) epidemic metrics were fit as a function of mean A(H1N1) or B epidemic size using Gaussian GLMs (inverse link: epidemic size, peak incidence; log link: effective R_t) or Beta GLMs (epidemic intensity) with 1000 bootstrap resamples.



1498
 1499 **Figure 6. Variable importance rankings from conditional inference random forest models**
 1500 **predicting A(H3N2) epidemic dynamics.** Ranking of variables in predicting regional A(H3N2) **A.**
 1501 epidemic size, **B.** peak incidence, **C.** effective reproduction number, Rt, **D.** epidemic intensity, and **E.**
 1502 subtype dominance. Each forest was created by generating 3,000 regression trees from a repeated
 1503 leave-one-season-out cross-validated sample of the data. Variables are ranked by their conditional
 1504 permutation importance, with differences in prediction accuracy scaled by the total (null model) error.
 1505 Black error bars are 95% confidence intervals of conditional permutation scores. Abbreviations: HI titer =
 1506 hemagglutination inhibition log₂ titer distance, t - 1 = one-season lag, t - 2 = two-season lag, LBI = local
 1507 branching index, peak = peak incidence, distance to vaccine = epitope distance between currently
 1508 circulating strains and the recommended vaccine strain, VE = vaccine effectiveness.



1509
 1510 **Figure 7. Observed versus predicted values of seasonal region-specific A(H3N2) A. epidemic size,**
 1511 **B. peak incidence, C. effective reproduction number, Rt, D. epidemic intensity, and E. subtype**
 1512 **dominance from conditional random forest models.** Results are faceted by HHS region and epidemic
 1513 **metric.** Point color and size corresponds to the degree of hemagglutinin (H3) epitope distance in viruses
 1514 circulating in season t versus viruses circulating two seasons ago ($t - 2$). Large, yellow points indicate
 1515 seasons with high antigenic novelty, and small blue points indicate seasons with low antigenic novelty.
 1516 Regional Spearman's correlation coefficients and associated P-values are in the top left section of each
 1517 facet.

1518 **Tables**

1519

1520 **Table 1. Evolutionary indicators of seasonal viral fitness.** Evolutionary indicators are labeled by the
 1521 influenza gene for which data are available (hemagglutinin, HA or neuraminidase, NA), the type of data
 1522 they are based on, and the component of influenza fitness they represent. Table format is adapted from
 1523 Huddleston et al., 2020 [35].

1524

Evolutionary indicator	Influenza gene	Data type	Fitness category	Citations
Mean HI titer log ₂ distance from the prior season	HA	Hemagglutinin inhibition assays using ferret sera	Antigenic drift	Huddleston et al., 2020; Neher et al., 2016
Mean epitope distance from the prior season	HA and NA	Sequences	Antigenic drift	Bhatt et al., 2011; Bush et al., 1999; Krammer, unpublished; Webster and Laver, 1980; Wiley et al., 1981; Wilson and Cox, 1990; Wolf et al., 2010
Mean receptor binding site distance from the prior season	HA	Sequences	Antigenic drift	Koel et al., 2013
Mutational load (mean non-epitope distance from the prior season)	HA and NA	Sequences	Functional constraint	Łuksza and Lässig, 2014
Mean stalk “footprint” distance from the prior season	HA	Sequences	Negative control	Kirkpatrick et al., 2018
Mean local branching index	HA and NA	Sequences	Clade growth	Huddleston et al., 2020; Łuksza and Lässig, 2014
Shannon entropy of local branching index	HA and NA	Sequences	Diversity of clade growth rates	Huddleston et al., 2020; Neher et al., 2014

1525

1526

1527 **Table 2. Seasonal metrics of A(H3N2) epidemic dynamics.** Epidemic metrics are defined and labeled
 1528 by which outcome category they represent.
 1529

Epidemic Outcome	Definition	Outcome category	Citations
Epidemic size	Cumulative weekly incidence	Burden	
Peak incidence	Maximum weekly incidence	Burden	
Maximum time-varying effective reproduction number, R_t	The number of secondary cases arising from a symptomatic index case, assuming conditions remain the same	Transmissibility	Cori et al., 2013; Scott et al., 2021
Epidemic intensity	Inverse Shannon entropy of the weekly incidence distribution (i.e., the spread of incidence across the season)	Sharpness of the epidemic curve	Dalziel et al., 2018
Subtype dominance	The proportion of influenza positive samples typed as A(H3N2)	Viral activity	
Excess pneumonia and influenza mortality attributable to A(H3N2) virus	Mortality burden in excess of a seasonally adjusted baseline	Severity	Hansen et al., 2022; Simonsen and Viboud, 2012
Onset week	Winter changepoint in incidence	Timing	Charu et al., 2017
Peak week	First week of maximum incidence	Timing	
Spatiotemporal synchrony	Variation (s.d.) in regional onset or peak timing	Speed	Viboud et al., 2006
Onset to peak	Number of days between onset week and peak week	Speed	
Seasonal duration	Number of weeks with non-zero incidence	Speed	

1530


1531 **Table 3. Predictors of seasonal A(H3N2) epidemic burden, transmissibility, intensity, and subtype**
1532 **dominance.** Variables retained in the best fit model for each epidemic outcome were determined by BIC.
1533

Outcome	Best Minimal Model ¹	R ²	Adj. R ²	RMSE
Epidemic Size	H3 epitope distance (t-2) + H1 epidemic size + H3 epidemic size (t-1)	0.74	0.69	9.88
Peak Incidence	H3 epitope distance (t-2) + H1 epidemic size + Dominant IAV Subtype (t-1)	0.69	0.63	2.09
Effective Rt	H1 titer distance (t-2) + H1 epidemic size + H3 LBI Diversity (t-1)	0.71	0.65	0.1
Epidemic Intensity	H1 titer distance (t-2) + N2 distance to vaccine strain + vaccination coverage (t-1)	0.79	0.75	0.07
Subtype Dominance	H3 epitope distance (t-2) + N2 epitope distance (t-1) + Dominant IAV Subtype (t-1)	0.56	0.48	0.2

1534
1535 ¹Candidate models were limited to 3 independent variables and considered all combinations of the top 10
1536 ranked predictors from conditional inference random forest models (Figure 6).


1537

Supplementary Figures




1538

1539 **Figure S1. Comparison of seasonal antigenic drift measured by substitutions at hemagglutinin**
1540 **(H3) epitope sites and HI titer measurements, from 1997-1998 to 2018-2019.** We used Spearman
1541 correlation tests to measure associations between H3 epitope distance and HI titer distance at **A.** one-
1542 season lags and **B.** two-season lags. Seasonal antigenic distance is the mean distance between strains
1543 circulating in season t and strains circulating in the prior season $t-1$ year (one season lag) or two
1544 seasons ago $t-2$ years (two season lag). Seasonal distances are scaled because epitope distance and
1545 HI titer distance use different units of measurement. Point labels indicate the current influenza season,
1546 and point color denotes the relative timing of influenza seasons, with earlier seasons shaded dark purple
1547 (e.g., 1997-1998) and later seasons shaded light yellow (e.g., 2018-2019). H3 epitope distance and HI
1548 titer (tree model) distance at two-season lags capture expected “jumps” in antigenic drift during key
1549 seasons previously associated with major antigenic transitions [32], such as the SY97 cluster seasons
1550 (1997-1998, 1998-1999, 1999-2000) and the FU02 cluster season (2003-2004).



1551
 1552 **Figure S2. Pairwise correlations between H3 and N2 evolutionary indicators (one season lags).** We
 1553 measured Spearman's correlations between seasonal measures of H3 and N2 evolution, including H3
 1554 RBS distance, H3 epitope distance, H3 non-epitope distance, H3 stalk footprint distance, HI titer distance,
 1555 N2 epitope distance based on 223 or 53 epitope sites, N2 non-epitope distance, mean clade growth of H3
 1556 and N2 (local branching index, LBI), and the Shannon entropy of H3 and N2 LBI values. Seasonal
 1557 distances were estimated as the mean distance between strains circulating in the current season t and
 1558 those circulating in the prior season ($t-1$). The Benjamini and Hochberg method was used to adjust P-
 1559 values for multiple testing. The color of each circle indicates the strength and direction of the association,
 1560 from dark red (strong positive correlation) to dark blue (strong negative correlation). Stars within circles
 1561 indicate statistical significance (adjusted $P < 0.05$).



1562

1563

1564

1565

1566

1567

1568


1569

1570


1571

1572

Figure S3. Pairwise correlations between H3 and N2 evolutionary indicators (two season lags). We measured Spearman's correlations between seasonal measures of H3 and N2 evolution, including H3 RBS distance, H3 epitope distance, H3 non-epitope distance, H3 stalk footprint distance, HI titer distance (tree model), N2 epitope distance based on 223 or 53 epitope sites, N2 non-epitope distance, mean clade growth of H3 and N2 (local branching index, LBI), and the Shannon entropy of H3 and N2 LBI values. Seasonal distances were estimated as the mean distance between strains circulating in the current season t and those circulating in the prior season ($t - 1$). The Benjamini and Hochberg method was used to adjust P-values for multiple testing. The color of each circle indicates the strength and direction of the association, from dark red (strong positive correlation) to dark blue (strong negative correlation). Stars within circles indicate statistical significance (adjusted $P < 0.05$).




1573
 1574 **Figure S4. Comparison of seasonal antigenic drift measured by substitutions at hemagglutinin**
 1575 **(H3) and neuraminidase (N2) epitope sites, from 1997-1998 to 2018-2019.** We used Spearman
 1576 correlation tests to measure associations between H3 epitope distance and N2 epitope distance at **A.**
 1577 one-season lags and **B.** two-season lags. Seasonal epitope distance is the mean distance between
 1578 strains circulating in season t and strains circulating in the prior season $t - 1$ (one season lag) or two
 1579 seasons ago $t - 2$ (two season lag). Point labels indicate the current influenza season, and point color
 1580 denotes the relative timing of influenza seasons, with earlier seasons shaded dark purple (e.g., 1997-
 1581 1998) and later seasons shaded light yellow (e.g., 2018-2019). N2 epitope distance at one-season lags
 1582 captures expected “jumps” in antigenic drift during key seasons previously associated with major
 1583 antigenic transitions [32], such as the SY97 cluster seasons (1997-1998, 1998-1999, 1999-2000) the
 1584 FU02 cluster season (2003-2004), and the CA04 cluster season (2004-2005).




1585
1586 **Figure S5. Intensity of weekly incidence of A. influenza A(H1N1) and B. influenza B in ten HHS**
1587 **regions, 1997 - 2019.** Seasonal and pandemic A(H1N1) were combined as A(H1N1), and the Victoria
1588 and Yamagata lineages of influenza B were combined as influenza B. White tiles indicate weeks when
1589 either influenza-like-illness cases or virological data were not reported. Data for Region 10 were not
1590 available in seasons prior to 2009.

1591




1592


1593 **Figure S6. Pairwise correlations between seasonal A(H3N2), A(H1N1), and B epidemic metrics.** We
 1594 measured Spearman's correlations among indicators of A(H3N2) epidemic timing, including onset week,
 1595 peak week, regional variation (s.d.) in onset and peak timing, and the number of days from onset to peak,
 1596 indicators of A(H3N2) epidemic magnitude, including epidemic intensity (i.e., the "sharpness" of the
 1597 epidemic curve), transmissibility (maximum effective reproduction number, R_t), subtype dominance
 1598 patterns, epidemic size, and peak incidence. We also considered relationships between the circulation of
 1599 other types/subtypes and A(H3N2) epidemic burden and timing. The Benjamini and Hochberg method
 1600 was used to adjust P-values for multiple testing. The color of each circle indicates the strength and
 1601 direction of the association, from dark red (strong positive correlation) to dark blue (strong negative
 1602 correlation). Stars within circles indicate statistical significance (adjusted $P < 0.05$).




1603
 1604 **Figure S7. Univariate correlations between A(H3N2) viral fitness and epidemic impact.** Mean
 1605 Spearman correlation coefficients, 95% confidence intervals of correlation coefficients, and corresponding
 1606 p-values of bootstrapped (N = 1000) viral fitness indicators (rows) and epidemic metrics (columns). Point
 1607 color indicates the strength and direction of the association, from dark red (strong positive correlation) to
 1608 dark blue (strong negative correlation), and stars indicate statistical significance (* P < 0.05, ** P < 0.01,
 1609 *** P < 0.001). Abbreviations: HI = hemagglutination inhibition, RBS: receptor binding site, t - 1 = one-
 1610 season lag, t - 2 = two-season lag, LBI = local branching index.



1611
 1612 **Figure S8. Low diversity in the growth rates of circulating A(H3N2) clades is associated with more**
 1613 **intense epidemics and higher transmissibility.** A(H3N2) effective R_t and epidemic intensity negatively
 1614 correlate with the diversity of LBI values among circulating A(H3N2) lineages in the current or prior
 1615 season, measured by the Shannon entropy of **A.** H3 local branching index (LBI) values in the prior
 1616 season ($t-1$), and **B.** the Shannon entropy of N2 LBI values in the current season t . LBI values are
 1617 scaled to aid in direct comparisons of H3 and N2 LBI diversity. Point color indicates the dominant
 1618 influenza A subtype based on CDC influenza season summary reports (red: A(H3N2), blue: A(H1N1),
 1619 purple: A(H1N1)pdm09, orange: A(H3N2)/A(H1N1)pdm09 co-dominant), and vertical bands are 95%
 1620 confidence intervals of regional estimates. Mean A(H3N2) epidemic metric values were fit as a function of
 1621 seasonal LBI diversity using Gaussian GLMs (effective R_t : inverse link) or Beta GLMs (epidemic intensity:
 1622 logit link) with 1000 bootstrap resamples.



1623
 1624 **Figure S9. Excess influenza A(H3N2) mortality increases with H3 and N2 antigenic drift, but**
 1625 **correlations are not statistically significant.** The number of excess influenza deaths attributable to
 1626 A(H3N2) (per 100,000 people) were estimated from a seasonal regression model fit to weekly pneumonia
 1627 and influenza-coded deaths [127]. Seasonal epitope distance is the mean distance between strains
 1628 circulating in season t and those circulating in the prior season ($t-1$) or two seasons ago ($t-2$).
 1629 Distances are scaled to aid in direct comparison of evolutionary indicators. Point color indicates the
 1630 dominant influenza A subtype based on CDC influenza season summary reports (red: A(H3N2), blue:
 1631 A(H1N1), purple: A(H1N1)pdm09, orange: A(H3N2)/A(H1N1)pdm09 co-dominant), and vertical bars are
 1632 95% confidence intervals of excess mortality estimates. National excess mortality estimates were fit as a
 1633 function of seasonal H3 or N2 epitope distance using Gaussian GLMs (log link) with 1000 bootstrap
 1634 resamples.



1635


1636

1637

1638


1639

Figure S10. Regional patterns of influenza type and subtype incidence from seasons 1997-1998 to 2018-2019. Pie charts represent the proportion of influenza positive samples that were typed as A(H3N2), A(H1N1) or A(H1N1)pdm09, and B in each HHS region. Data for Region 10 (purple) were not available in seasons prior to the 2009 A(H1N1) pandemic.




1640


1641 **Figure S11. Univariate correlations between A(H3N2) viral fitness and epidemic timing.** Mean
 1642 Spearman correlation coefficients, 95% confidence intervals of correlation coefficients, and corresponding
 1643 p-values of bootstrapped (N = 1000) viral fitness indicators (columns) and epidemic timing metrics.
 1644 Epidemic timing metrics are the week of epidemic onset, regional variation (s.d.) in onset timing, the week
 1645 of epidemic peak, regional variation (s.d.) in peak timing, the number of days between epidemic onset
 1646 and peak, and seasonal duration. Color indicates the strength and direction of the association, from dark
 1647 red (strong positive correlation) to dark blue (strong negative correlation), and stars indicate statistical
 1648 significance (* P < 0.05, ** P < 0.01, *** P < 0.001). Abbreviations: HI = hemagglutination inhibition, RBS:
 1649 receptor binding site, t - 1 = one-season lag, t - 2 = two-season lag, LBI = local branching index.




1650
 1651 **Figure S12. Seasonal duration increases with diversity in clade growth rates of circulating H3 and**
 1652 **N2 lineages, measured as the Shannon entropy of local branching index (LBI) values. A.** H3 LBI
 1653 diversity and **B.** N2 LBI diversity during the current season positively correlate with seasonal duration. LBI
 1654 values are scaled to aid in direct comparisons of H3 and N2 LBI diversity. Point color indicates the
 1655 dominant influenza A subtype based on CDC influenza season summary reports (red: A(H3N2), blue:
 1656 A(H1N1), purple: A(H1N1)pdm09, orange: A(H3N2)/A(H1N1)pdm09 co-dominant). Mean values of
 1657 regional season duration were fit as a function of H3 LBI diversity or N2 LBI diversity using Gaussian
 1658 GLMs (inverse link) with 1000 bootstrap resamples.




1659
1660 **Figure S13. Epidemic speed increases with N2 antigenic drift.** N2 epitope distance correlates with
1661 fewer days from epidemic onset to peak (A), while the relationship between H3 epitope distance and
1662 epidemic speed is less apparent (B). Seasonal epitope distance is the mean distance between strains
1663 circulating in season t and those circulating in the prior season ($t - 1$) or two seasons ago ($t - 2$).
1664 Distances are scaled to aid in direct comparison of evolutionary indicators. Point color indicates the
1665 dominant influenza A subtype based on CDC influenza season summary reports (red: A(H3N2), blue:
1666 A(H1N1), purple: A(H1N1)pdm09, orange: A(H3N2)/A(H1N1)pdm09 co-dominant). Mean values of
1667 regional days from onset to peak were fit as a function of H3 or N2 epitope distance using Gamma GLMs
1668 (inverse link) with 1000 bootstrap resamples.




1669
 1670 **Figure S14. The timing of epidemic onsets and peaks are weakly correlated with H3 and N2**
 1671 **antigenic change. A.** Epidemic onsets are earlier in seasons with increased H3 epitope distance ($t-2$),
 1672 but the correlation is not statistically significant. **B.** Epidemic peaks are earlier in seasons with increased
 1673 H3 epitope distance ($t-2$) or increased N2 epitope distance ($t-1$), but correlations are not statistically
 1674 significant. Seasonal epitope distance is the mean distance between strains circulating in season t
 1675 and those circulating in the prior season ($t-1$) or two seasons ago ($t-2$). Distances are scaled to aid in
 1676 direct comparison of evolutionary indicators. Point color indicates the dominant influenza A subtype
 1677 based on CDC influenza season summary reports (red: A(H3N2), blue: A(H1N1), purple: A(H1N1)pdm09,
 1678 orange: A(H3N2)/A(H1N1)pdm09 co-dominant). Mean values of regional epidemic onsets and peaks
 1679 were fit as a function of H3 or N2 epitope distance using LMs with 1000 bootstrap resamples.



1680
 1681 **Figure S15. Univariate correlations between A(H3N2) antigenic change and the age distribution of**
 1682 **outpatient influenza-like illness (ILI) cases.** Mean Spearman correlation coefficients, 95% confidence
 1683 intervals of correlation coefficients, and corresponding p-values of bootstrapped (N = 1000) evolutionary
 1684 indicators (rows) and the proportion of ILI cases in individuals aged < 5 years, 5-24 years,
 1685 and ≥ 65 years (columns). Color indicates the strength and direction of the association, from dark red
 1686 (strong positive correlation) to dark blue (strong negative correlation), and stars indicate statistical
 1687 significance (* P < 0.05, ** P < 0.01, *** P < 0.001). Abbreviations: HI = hemagglutination inhibition, RBS:
 1688 receptor binding site, t - 1 = one-season lag, t - 2 = two-season lag.




1689
 1690
 1691 **Figure S16. N2 epitope distance correlates with the age distribution of outpatient influenza-like**
 1692 **illness (ILI) cases.** Seasonal epitope distance is the mean distance between strains circulating in season
 1693 t and those circulating in the prior season ($t-1$) or two seasons ago ($t-2$). Distances are scaled to aid in
 1694 direct comparison of evolutionary indicators. Point color indicates the dominant influenza A subtype
 1695 based on CDC influenza season summary reports (red: A(H3N2), blue: A(H1N1), purple: A(H1N1)pdm09,
 1696 orange: A(H3N2)/A(H1N1)pdm09 co-dominant), and vertical bars are 95% confidence intervals of
 1697 regional age distribution estimates. The fraction of cases in each age group were fit as a function of
 seasonal H3 or N2 epitope distance using Beta GLMs (logit link) with 1000 bootstrap resamples.




1698
 1699 **Figure S17. National excess influenza A(H3N2) mortality decreases with A(H1N1) epidemic size**
 1700 **but not B epidemic size.** Excess influenza deaths attributable to A(H3N2) (per 100,000 people) were
 1701 estimated from a seasonal regression model fit to weekly pneumonia and influenza-coded deaths. Point
 1702 color indicates the dominant influenza A subtype based on CDC influenza season summary reports (red:
 1703 A(H3N2), blue: A(H1N1), purple: A(H1N1)pdm09, orange: A(H3N2)/A(H1N1)pdm09 co-dominant), and
 1704 vertical bands are 95% confidence intervals of model estimates. National excess mortality estimates were
 1705 fit as a function of seasonal A(H1N1) or B epidemic size using Gaussian GLMs (log link) with 1000
 1706 bootstrap resamples.


All seasons



Pre-2009 seasons




Post-2009 seasons




Dominant IAV: ● H3 ● H1 ● H1pdm ● H3/H1pdm


1707
 1708 **Figure S18. The effect of influenza A(H1N1) epidemic size on A(H3N2) epidemic burden during the**
 1709 **entire study period (1997-2019) (top), pre-2009 seasons (middle), and post-2009 seasons (bottom).**
 1710 Influenza A(H1N1) epidemic size inversely correlates with A(H3N2) epidemic size, peak incidence,
 1711 transmissibility (maximum effective reproduction number, Rt), and epidemic intensity. Point color indicates
 1712 the dominant influenza A virus (IAV) subtype based on CDC influenza season summary reports (red:
 1713 A(H3N2), blue: A(H1N1), purple: A(H1N1)pdm09, orange: A(H3N2)/A(H1N1)pdm09 co-dominant), and
 1714 vertical and horizontal bands are 95% confidence intervals of regional estimates. Seasonal mean
 1715 A(H3N2) epidemic metrics were fit as a function of mean A(H1N1) epidemic size using Gaussian GLMs
 1716 (epidemic size, peak incidence: inverse link; effective Rt: log link) or Beta GLMs (epidemic intensity: logit
 1717 link) with 1000 bootstrap resamples.




1718
 1719 **Figure S19. Wavelet analysis of influenza A and B epidemic timing.** **A.** A(H3N2) incidence precedes
 1720 A(H1N1) incidence in most seasons. Although A(H1N1) incidence sometimes leads or is in phase with
 1721 A(H3N2) incidence (negative or zero phase lag), the direction of seasonal phase lags is not clearly
 1722 associated with A(H1N1) epidemic size. **B.** A(H3N2) incidence leads B incidence (positive phase lag)
 1723 during each season, irrespective of B epidemic size. Point color indicates the dominant influenza A
 1724 subtype based on CDC influenza season summary reports (red: A(H3N2), blue: A(H1N1), purple:
 1725 A(H1N1)pdm09, orange: A(H3N2)/A(H1N1)pdm09 co-dominant), and vertical bars are 95% confidence
 1726 intervals of regional estimates. To estimate the relative timing of influenza subtype incidences, phase
 1727 angle differences were calculated as phase in A(H3N2) minus phase in A(H1N1) (or B), with a positive
 1728 value indicating that A(H1N1) (or B) incidence lags A(H3N2) incidence. To calculate seasonal phase lags,
 1729 we averaged pairwise phase angle differences from epidemic week 40 to epidemic week 20. Seasonal
 1730 phase lags were fit as a function of seasonal A(H1N1) or B epidemic size using LMs with 1000 bootstrap
 1731 resamples.



1732
 1733 **Figure S20. Variable importance rankings from LASSO models predicting A(H3N2) epidemic**
 1734 **dynamics.** Ranking of variables in predicting seasonal A(H3N2) **A.** epidemic size, **B.** peak incidence, **C.**
 1735 transmissibility (effective reproduction number, Rt), **D.** epidemic intensity (inverse Shannon entropy), and
 1736 **E.** subtype dominance. Models were tuned using a repeated leave-one-season-out cross-validated
 1737 sample of the data. Variables are ranked by their coefficient estimates, with differences in prediction
 1738 accuracy scaled by the total (null model) error. Abbreviations: HI titer = hemagglutination inhibition log₂
 1739 titer distance, t - 1 = one-season lag, t - 2 = two-season lag, LBI = local branching index, peak = peak
 1740 incidence, distance to vaccine = epitope distance between currently circulating strains and the
 1741 recommended vaccine strain, VE = vaccine effectiveness.



1742
 1743 **Figures S21. Relationships between the predictive accuracy of random forest models and H3**
 1744 **epitope distance.** Root mean squared errors between observed and model-predicted values were
 1745 averaged across regions for each season, and results are faceted according to epidemic metric. Point
 1746 color corresponds to the degree of H3 epitope distance in viruses circulating in season t relative to those
 1747 circulating two seasons ago ($t - 2$), with bright yellow points indicating seasons with greater antigenic
 1748 novelty. Spearman correlation coefficients and associated P-values are provided in the top left section of
 1749 each facet.



1750
 1751 **Figures S22. Relationships between the predictive accuracy of random forest models and N2**
 1752 **epitope distance** Root mean squared errors between observed and model-predicted values were
 1753 averaged across regions for each season, and results are faceted according to epidemic metric. Point
 1754 color corresponds to the degree of N2 epitope distance in viruses circulating in season t relative to those
 1755 circulating in the prior season ($t - 1$), with bright yellow points indicating seasons with greater antigenic
 1756 novelty. Spearman correlation coefficients and associated P-values are provided in the top left section of
 1757 each facet.